Browse by Poster Presenter

Schedule at a Glance

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

S
Sánchez Morillas, Raúl

Son Espases University Hospital
(P 13) GENOMIC PROFILING OF ADULT SOFT TISSUE SARCOMAS FROM A SINGLE CENTER EXPERIENCE
Raúl Sánchez Morillas
Favorite
(P 322) A NEW PLAYER IN SOFT TISSUE SARCOMA PROGRESSION: WNT5A IS A PROGNOSIS BIOMARKER AND A POTENTIAL ACTIONABLE TARGET
Raúl Sánchez Morillas
Favorite
Säljö, Karin

University of Gothenburg, Institute of Clinical Scinces
(P 139) CHARACTERIZATION OF GLYCOSPHINGOLIPIDS IN HUMAN LEIOMYOSARCOMA
Karin Säljö
Favorite
Saavedra, Omar

NEXT Oncology Hospital Quionsalud Barcelona
(P 337) OMX-0407 A NOVEL SPECTRUM-SELECTIVE SMALL MOLECULE KINASE INHIBITOR IS ACTIVE IN THE TREATMENT OF ANGIOSARCOMA
Omar Saavedra
Favorite
Saba, Karim

Lund University
(P 03) CDK4 IS CO-AMPLIFIED WITH EITHER TP53 PROMOTER GENE FUSIONS OR MDM2 THROUGH DISTINCT MECHANISMS IN OSTEOSARCOMA
Karim Saba
Favorite
(P 26) SARCDBASE: A TOOL FOR DETECTION OF GENETIC ALTERATIONS IN SARCOMA
Karim Saba
Favorite
Sachdeva, Ishita

Washington University in St Louis
(P 187) BRIDGING THE GAP: UNDERSTANDING THE CURRENT TREATMENT RESPONSES TO ENHANCE THE STANDARD OF CARE AND OUTCOMES FOR MALIGNANT PERIPHERAL NERVE SHEATH TUMORS
Ishita Sachdeva
Favorite
Sachs, Elizabeth

Duke
(P 54) CHONDROBLASTIC OSTEOSARCOMA IS A RISK FACTOR FOR LOCAL RECURRENCE IN PATIENTS WITH SKELETAL OSTEOSARCOMA
Elizabeth Sachs
Favorite
Saeki, Kohei

Okayama University of Science
(P 01) A PILOT STUDY ON SINGLE-NUCLEUS RNA SEQUENCING IN CANINE SOFT TISSUE SARCOMAS
Kohei Saeki
Favorite
Saiduzzaman, S. M.

University of California Santa Cruz, Electrical and Computer Engineering, Genomics Institute
(P 147) INVESTIGATING THE POTENTIAL OF EXTRACELLULAR VESICLE BIOMARKERS IN SYNOVIAL SARCOMA DETECTION
S. M. Saiduzzaman
Favorite
Saigh, Shannon

University of Miami Miller School of Medicine
(P 434) UTILIZATION OF IMAGING MASS CYTOMETRY TO EVALUATE THE IMMUNE LANDSCAPE OF PEDIATRIC AND ADULT PATIENTS WITH SARCOMA TREATED WITH AN AUTOLOGOUS DENDRITIC CELL VACCINE
Shannon Saigh
Favorite
Saint-Yves, Hugo

CEMTL
(P 153) PATTERNS, MANAGEMENT AND SURVIVAL OUTCOMES OF PATIENTS WITH EPITHELIOID HEMANGIOENDOTHELIOMA: A NATIONWIDE ANALYSIS FROM THE CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION DATABASE
Hugo Saint-Yves
Favorite
(P 212) REFERENCE SYSTEM OPTIMIZATION, ANALYSES OF THE IMPLEMENTATION OF A PROVINCIAL MULTIDISCIPLINARY SARCOMA NETWORK
Hugo Saint-Yves
Favorite
Sairyo, Koichi

Tokushima University
(P 138) ACCURACY AND COMPLICATIONS OF CORE NEEDLE BIOPSY OF PERIPHERAL NERVE TUMORS
Koichi Sairyo
Favorite
Sakai, Hideki

Hyogo Cancer Center
(P 168) EFFICACY OF LOW-DOSE IMATINIB IN A PATIENT WITH A GIST WITH KIT EXON 11 W557_K558 DELETION
Hideki Sakai
Favorite
Sakai, Tomohisa

Nagoya university hospital
(P 280) SURGICAL OUTCOMES OF PELVIC CHONDROSARCOMA WITH A FOCUS ON WALKING ABILITY
Tomohisa Sakai
Favorite
Salawu, Abdulazeez

Mount Sinai Hospital and Princess Margaret Cancer Centre/University of Toronto
(P 320) WHAT IS THE ROLE OF CHEMOTHERAPY IN PATIENTS (PTS) WITH SPINDLE CELL/SCLEROSING RHABDOMYOSARCOMA (SCRMS): A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Abdulazeez Salawu
Favorite
Salazar-Arcila, Carolina

University of Calgary
(P 236) INTERFERON STIMULATED GENE SCORES ARE ELEVATED IN THE MYELOID COMPARTMENT OF MURINE KP UNDIFFERENTIATED PLEOMORPHIC TUMORS TREATED WITH TRANSLATIONAL STING AGONISTS
Carolina Salazar-Arcila
Favorite
(P 239) INVESTIGATING HOW TUMOUR ASSOCIATED MACROPHAGES INFLUENCE THE EFFICACY OF CAR T THERAPY IN A MURINE MODEL OF SOFT TISSUE SARCOMA
Carolina Salazar-Arcila
Favorite
(P 327) CHARACTERIZATION OF TWO NOVEL IMMUNE COMPETENT, MURINE MODELS OF SOFT TISSUE SARCOMA
Carolina Salazar-Arcila
Favorite
(P 333) ESTIMATING IMMUNE INFILTRATES OF NOVEL GENETICALLY ENGINEERED MOUSE MODELS OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Carolina Salazar-Arcila
Favorite
Saleh, Mohammad

University of Miami Miller School of Medicine and Jackson Health Systems
(P 381) OLIGOMETASTATIC LEIOMYOSARCOMA: ASSOCIATION BETWEEN TREATMENT TYPE, METASTATIC PATTERN AND SURVIVAL
Mohammad Saleh
Favorite
Saleh, Ramy

MUCH
(P 153) PATTERNS, MANAGEMENT AND SURVIVAL OUTCOMES OF PATIENTS WITH EPITHELIOID HEMANGIOENDOTHELIOMA: A NATIONWIDE ANALYSIS FROM THE CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION DATABASE
Ramy Saleh
Favorite
(P 293) CIC-REARRANGED SOFT TISSUE SARCOMAS: DOES CHEMOTHERAPY CHANGE NATURAL HISTORY AND PROGNOSIS? A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Ramy Saleh
Favorite
(P 320) WHAT IS THE ROLE OF CHEMOTHERAPY IN PATIENTS (PTS) WITH SPINDLE CELL/SCLEROSING RHABDOMYOSARCOMA (SCRMS): A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Ramy Saleh
Favorite
Salib, Alice

Children's Cancer Institute
(P 299) EXPLORING THE POTENTIAL OF PHOSPHOPROTEOMIC PROFILING FOR TARGET DISCOVERY IN HIGH-RISK OSTEOSARCOMA: A PATHWAY TO NOVEL THERAPIES?
Alice Salib
Favorite
Salvatore, Daniela

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
(P 376) IMPACT OF SITE OF ORIGIN ON THE PROGNOSIS OF PATIENTS WITH PRIMARY RESECTABLE NON-UTERINE ABDOMINAL LEIOMYOSARCOMA
Daniela Salvatore
Favorite
Salyer, Hannah

Texas Tech University Health Sciences Center
(P 292) CHARACTERIZATION OF TELOMERE MAINTENANCE MECHANISMS IN OSTEOSARCOMA PATIENT-DERIVED LABORATORY MODELS
Hannah Salyer
Favorite
Samà, Laura

IRCCS - Humanitas Research Hospital
(P 362) A NEW ROCK BAND FOR DIAPHRAGMATIC RECONSTRUCTION IN LEFT RETROPERITONEAL SARCOMA SURGERY
Laura Samà
Favorite
(P 363) A NEW SURGICAL TECHNIQUE FOR THE RECONSTRUCTION OF INGUINAL 'NEOLIGAMENT' AFTER SOFT TISSUE SARCOMA RESECTION
Laura Samà
Favorite
(P 373) EVALUATION OF HISTOLOGIC ORGAN INFILTRATION (HOI) AND VISCERAL RESECTION MARGINS (VRM) IN PRIMARY RETROPERITONEAL SARCOMAS: PROGNOSTIC IMPLICATIONS FOR LOCAL RECURRENCE
Laura Samà
Favorite
(P 388) THE ROAD TO CURATIVE SURGERY IN RETROPERITONEAL SOFT TISSUE SARCOMA: A DIFFERENT PATH IN THE ELDERLY?
Laura Samà
Favorite
(P 389) THE ROLE OF NUTRITIONAL STATUS ON POSTOPERATIVE AND ONCOLOGICAL OUTCOMES IN RETROPERITONEAL SARCOMA
Laura Samà
Favorite
Sandhu, Jagteshwar

University of Miami Miller School of Medicine
(P 369) BLAND EMBOLIZATION AS ADJUNCT TREATMENT FOR HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA
Jagteshwar Sandhu
Favorite
Sanfilippo, Roberta

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 137) TARGETING PRIMARY AND SECONDARY ONCOGENIC DRIVERS IN RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMAS
Roberta Sanfilippo
Favorite
(P 160) UTERINE PECOMA: REPORT OF MOLECULAR AND CLINICAL FEATURES IN A SERIES OF PATIENTS TREATED AT A REFERRAL INSTITUTION
Roberta Sanfilippo
Favorite
(P 171) GASTROINTESTINAL STROMAL TUMOURS (GISTS) IN NEUROFIBROMATOSIS TYPE (NF1): A SINGLE-CENTER OBSERVATIONAL RETROSPECTIVE STUDY
Roberta Sanfilippo
Favorite
(P 368) AGGRESSIVE PERINEAL ANGIOMYXOMA UNDERGOING SYSTEMIC TREATMENT: AN UPDATED REPORT OF 8-YEARS' EXPERIENCE IN A REFERRAL CENTER
Roberta Sanfilippo
Favorite
(P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS
Roberta Sanfilippo
Favorite
(P 376) IMPACT OF SITE OF ORIGIN ON THE PROGNOSIS OF PATIENTS WITH PRIMARY RESECTABLE NON-UTERINE ABDOMINAL LEIOMYOSARCOMA
Roberta Sanfilippo
Favorite
(P 415) TRABECTEDIN PLUS OLAPARIB IN ADVANCED LEIOMYOSARCOMA PROGRESSING AFTER STANDARD TREATMENTS FOR ADVANCED DISEASE: A POOLED ANALYSIS OF TOMAS AND TOMAS2 STUDIES FROM THE ITALIAN SARCOMA GROUP.
Roberta Sanfilippo
Favorite
(P 420) CELLULARITY DEGREES IN PRIMARY MYXOID LIPOSARCOMA: ASSOCIATION WITH TUMOR IMMUNE INFILTRATE AND PATIENT OUTCOMES
Roberta Sanfilippo
Favorite
Sangiolo, Dario

Department of Oncology, University of Turin
(P 345) TRANSCRIPTOMIC AND PHENOTYPIC CHARACTERIZATION OF AN IMMUNOCOMPETENT LEIOMYOSARCOMA MOUSE MODEL.
Dario Sangiolo
Favorite
Sankhala, Esha

University of California, Irvine
(P 140) CIRCULATING TUMOR DNA AS A TOOL OF SURVEILLANCE AND EARLY INDICATOR OF RELAPSE IN SARCOMA PATIENTS
Esha Sankhala
Favorite
Sankhala, Kamalesh

Samuel Oschin Cancer Center, Cedars Sinai Health System
(P 400) A LONG-TERM PHASE 4 STUDY TO EVALUATE THE RISK OF HEPATOTOXICITY ASSOCIATED WITH PEXIDARTINIB TREATMENT
Kamalesh Sankhala
Favorite
Santiago, Teresa

St. Jude Children's Research Hospital
(P 288) ANGIOA: A SAFETY AND TOLERABILITY STUDY OF TRIPLE ANTI-ANGIOGENIC THERAPY COMBINED WITH PD-L1 BLOCKADE IN PEDIATRIC, ADOLESCENT AND YOUNG ADULT RECURRENT/REFRACTORY SOLID TUMORS
Teresa Santiago
Favorite
Santoro, Armando

Humanitas Research Hospital
(P 124) ASSESSMENT OF THE MECHANISMS OF ACTION OF ERIBULIN IN PATIENTS WITH ADVANCED LIPOSARCOMA THROUGH THE EVALUATION OF THE RADIOLOGICAL, FUNCTIONAL AND TISSUE RESPONSE: A MONOCENTRIC PROSPECTIVE STUDY
Armando Santoro
Favorite
(P 155) PRIMARY MESENCHYMAL TUMORS OF THE HEART: A 8-YEARS, SINGLE INSTITUTION EXPERIENCE
Armando Santoro
Favorite
(P 290) ARTIFICIAL INTELLIGENCE-BASED COMPARISON OF ADULT AND ADOLESCENT AND YOUNG ADULTS (AYA) SARCOMAS: A PILOT STUDY
Armando Santoro
Favorite
Santoro, Armando

IRCCS Humanitas Research Hospital
(P 431) REAL-WORLD EXPERIENCE OF EFFICACY AND TOLERABILITY OF CONTINUOS INFUSION IFOSFAMIDE AMONG ADVANCED SOFT TISSUE AND BONE SARCOMAS PATIENTS: A SINGLE CENTRE RETROSPECTIVE COHORT.
Armando Santoro
Favorite
Santos, Miguel

Instituto Português de Oncologia de Lisboa
(P 128) DYNAMIC HETEROGENEITY AMONGST LIPOSARCOMAS
Miguel Santos
Favorite
Sapienza, Maria Rosaria

Hemolimphopathology, IEO - Istituto Europeo di Oncologia IRCCS
(P 86) RESPONSE TO MIFAMURTIDE AND TUMOR MICROENVIRONMENT: A DECONVOLUTION NANOSTRING ANALYSIS IN LOCALIZED OSTEOSARCOMA PATIENTS TREATED WITHIN THE ISG/OS2 CLINICAL TRIAL
Maria Rosaria Sapienza
Favorite
Sarchet, Patricia

The Ohio State University
(P 136) TARGETING MIR-138-5P TO TREAT DEDIFFERENTIATED LIPOSARCOMA
Patricia Sarchet
Favorite
Sarre Lazcano, Catherine

University of Toronto
(P 213) REGIONAL KNOWLEDGE TRANSLATION IN RETROPERITONEAL SARCOMAS: IMPACT OF AN EDUCATIONAL WEBINAR SERIES BY THE MEXICAN SARCOMA GROUP
Catherine Sarre Lazcano
Favorite
(P 376) IMPACT OF SITE OF ORIGIN ON THE PROGNOSIS OF PATIENTS WITH PRIMARY RESECTABLE NON-UTERINE ABDOMINAL LEIOMYOSARCOMA
Catherine Sarre Lazcano
Favorite
Sarre, Catherine

TARPSWG
(P 367) AGE AS A PROGNOSTIC FACTOR IN RETROPERITONEAL SARCOMA: A MULTICENTER LATIN AMERICAN STUDY
Catherine Sarre
Favorite
Sarthy, Jay

Seattle Children's Research Institute, University of Washington
(P 330) EFFICACY OF NON-CARDIOTOXIC ANTHRACYCLINES IN EWING SARCOMA
Jay Sarthy
Favorite
Sassi, Martina

Campus Bio-Medico University of Rome
(P 178) PREDICTION OF PRIMARY IMATINIB-REFRACTORY PATIENTS WITH LOCALLY ADVANCED OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) USING RADIOMICS AND ARTIFICIAL INTELLIGENCE (AI)
Martina Sassi
Favorite
Satterwhite, Audra

National Cancer Institute/National Institutes of Health
(P 163) CHARACTERIZATION OF INTRAHEPATIC RECURRENCE FOLLOWING LIVER-DIRECTED SURGERY IN PATIENTS WITH METASTATIC SDH-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST): RISE AND STABILIZATION OF THE GISTLETS
Audra Satterwhite
Favorite
Savage, Princess

Sarcoma Oncology Center
(P 251) UPDATE ON SAINT: A PHASE 2 STUDY USING TRABECTEDIN (T) IN COMBINATION WITH IPILIMUMAB (L) AND NIVOLUMAB (N) IN PREVIOUSLY TREATED SOFT TISSUE SARCOMA (NCT03138161)
Princess Savage
Favorite
Sayles, Leanne

UCSF
(P 292) CHARACTERIZATION OF TELOMERE MAINTENANCE MECHANISMS IN OSTEOSARCOMA PATIENT-DERIVED LABORATORY MODELS
Leanne Sayles
Favorite
Sbaraglia, Marta

University of Padua
(P 110) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF PLEOMORPHIC RHABDOMYOSARCOMA (P-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Marta Sbaraglia
Favorite
(P 111) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA (S-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Marta Sbaraglia
Favorite
(P 345) TRANSCRIPTOMIC AND PHENOTYPIC CHARACTERIZATION OF AN IMMUNOCOMPETENT LEIOMYOSARCOMA MOUSE MODEL.
Marta Sbaraglia
Favorite
(P 415) TRABECTEDIN PLUS OLAPARIB IN ADVANCED LEIOMYOSARCOMA PROGRESSING AFTER STANDARD TREATMENTS FOR ADVANCED DISEASE: A POOLED ANALYSIS OF TOMAS AND TOMAS2 STUDIES FROM THE ITALIAN SARCOMA GROUP.
Marta Sbaraglia
Favorite
Scallo, Frankie

Yale University
(P 98) A MULTIEPITOPE MRNA VACCINE FOR KAPOSI SARCOMA: AN IMMUNOINFORMATIC APPROACH
Frankie Scallo
Favorite
Scally, Christopher

University of Texas MD Anderson Cancer Center
(P 130) HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RESECTABLE RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA (DDLPS) TREATED WITH NEOADJUVANT CHECKPOINT BLOCKADE IN A RANDOMIZED PHASE II CLINICAL TRIAL.
Christopher Scally
Favorite
Scally, Christopher

The University of Texas MD Anderson Cancer Center
(P 360) TREATMENT OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR WITH BROMODOMAIN EXTRA TERMINAL INHIBITOR (BETI) IN COMBINATION WITH RADIOTHERAPY
Christopher Scally
Favorite
Schaefer, Inga-Marie

Brigham and Women's Hospital
(P 111) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA (S-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Inga-Marie Schaefer
Favorite
Schaffer, Moshe

Barzilai Medical Center, Ashkelon
(P 182) A NOVEL MODEL FOR THE DIRECT REFERRAL OF ONCOLOGIC PATIENTS IN A PUBLIC HEALTH CARE SYSTEM
Moshe Schaffer
Favorite
Schalper, Kurt

Yale University School of Medicine
(P 47) A PHASE 2 STUDY OF OLAPARIB IN METASTATIC IDH1 AND IDH2 MUTANT CHONDROSARCOMAS
Kurt Schalper
Favorite
Schelfaut, Sebastiaan

UZ Leuven
(P 291) CASE REPORT: RADICAL EN BLOC MULTI-LEVEL SPONDYLECTOMY FOR A LOCALLY RECURRENT OSTEOSARCOMA
Sebastiaan Schelfaut
Favorite
Schelling, Georg

SwissSarcomaNetwork
(P 184) A SYSTEMATIC REVIEW ABOUT CLINICAL PROGNOSTIC MODELS FOR SARCOMAS
Georg Schelling
Favorite
Scherer, Amanda

University of Iowa
(P 12) GENETIC LANDSCAPE OF MPNST DETERMINES METABOLIC STRATEGIES AND THERAPEUTIC OPPORTUNITIES FOR COPING WITH REDOX STRESS
Amanda Scherer
Favorite
Schiffman, Joshua

Peel Therapeutics; Huntsman Cancer Institute, University of Utah
(P 16) HOW TO GROW A BONE IN 60 DAYS: EXPLORING THE UNIQUE PRO-GROWTH, ANTI-CANCER ENVIRONMENT IN ELK ANTLERS
Joshua Schiffman
Favorite
Schleupner, Beatrice

Duke University School of Medicine
(P 16) HOW TO GROW A BONE IN 60 DAYS: EXPLORING THE UNIQUE PRO-GROWTH, ANTI-CANCER ENVIRONMENT IN ELK ANTLERS
Beatrice Schleupner
Favorite
Schmerling, Rafael

Latin American Cooperative Oncology Group (LACOG)
(P 192) CURRENT SCENARIO OF SARCOMA CLINICAL TRIALS IN SOUTH AMERICA: A REPORT BY THE LACOG SARCOMA GROUP
Rafael Schmerling
Favorite
(P 216) SARCOMA CARE PATHWAYS AND MULTIDISCIPLINARY TUMOR BOARDS IN LATIN AMERICA: AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
Rafael Schmerling
Favorite
(P 217) SARCOMA DRUG APPROVALS IN LATIN AMERICA COMPARED TO THE FDA AND EMA: AN ANALYSIS BY THE LACOG SARCOMA GROUP
Rafael Schmerling
Favorite
(P 219) SOCIAL MEDIA USE AMONG MEDICAL PROFESSIONALS THAT TREAT PATIENTS WITH SARCOMA IN LATIN AMERICA: RESULTS OF AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
Rafael Schmerling
Favorite
Schmidt, Holger

University of California Santa Cruz, Electrical and Computer Engineering, Genomics Institute
(P 147) INVESTIGATING THE POTENTIAL OF EXTRACELLULAR VESICLE BIOMARKERS IN SYNOVIAL SARCOMA DETECTION
Holger Schmidt
Favorite
Schmidt, Max

Indiana University School of Medicine
(P 384) REAL WORLD EXPERIENCE IN TREATING HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA: AN ULTRA-RARE VASCULAR TUMOR
Max Schmidt
Favorite
Schmidt, Ryan

Children's Hospital Los Angeles
(P 76) MOLECULAR AND CHROMOSOMAL MICROARRAY PROFILING OF OSTEOSARCOMA IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS: A SINGLE INSTITUTION REPORT
Ryan Schmidt
Favorite
Schoedel, Karen

University of Pittsburgh Medical Center
(P 117) THE TUMOR IMMUNE MICROENVIRONMENT OF DEDIFFERENTIATED SARCOMAS: DIGITAL SPATIAL PROFILING SHOWS IMMUNE TRANSCRIPTIONAL DIFFERENCES BETWEEN DEDIFFERENTIATED LIPOSARCOMA AND CHONDROSARCOMA
Karen Schoedel
Favorite
(P 240) INVESTIGATING MACROPHAGE POPULATION VARIABILITY IN METASTATIC SARCOMA SAMPLES
Karen Schoedel
Favorite
(P 258) COMPARING OUTCOMES FOLLOWING INTRALESIONAL VERSUS WIDE RESECTION PROCEDURES IN THE TREATMENT OF RENAL CELL CARCINOMA BONE METASTASES
Karen Schoedel
Favorite
Schöffski, Patrick

Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU Leuven
(P 181) UPDATED OVERALL SURVIVAL WITH RIPRETINIB VS SUNITINIB IN PATIENTS WITH SECOND-LINE ADVANCED GASTROINTESTINAL STROMAL TUMOR AND KIT EXON 11+17/18 MUTATIONS: CIRCULATING TUMOR DNA ANALYSIS FROM INTRIGUE
Patrick Schöffski
Favorite
(P 331) EFFICACY OF NOVEL UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN TARGETED ANTIBODY-DRUG CONJUGATES IN PATIENT-DERIVED XENOGRAFTS OF SOFT TISSUE SARCOMA
Patrick Schöffski
Favorite
(P 334) EXPANDING THE LANDSCAPE OF PRECLINICAL MODELS OF SYNOVIAL SARCOMA: FROM 2-DIMENSIONS TO 3-DIMENSIONS TO MICE
Patrick Schöffski
Favorite
(P 340) THE DNA MINOR GROOVE BINDING AGENTS ECUBECTEDIN AND PM54 DEMONSTRATE ANTITUMOR ACTIVITY IN PATIENT-DERIVED XENOGRAFT MODELS OF SOFT TISSUE SARCOMA
Patrick Schöffski
Favorite
Scholte, Claire

Leiden University Medical Center
(P 56) CHROME: PREDICTING CHONDROSARCOMA RISK OUTCOME FROM METHYLATION
Claire Scholte
Favorite
Scholten, A.N.

Netherlands Cancer Institute
(P 24) NEOADJUVANT CHEMOTHERAPY FOR RADIOTHERAPY ASSOCIATED ANGIOSARCOMA (RAAS) OF THE BREAST IMPROVES ONCOLOGICAL OUTCOMES
A.N. Scholten
Favorite
(P 349) LONG-TERM SURVIVAL OF PARTICIPANTS IN THE PASART-1 AND PASART-2 TRIALS OF NEO-ADJUVANT PAZOPANIB AND RADIOTHERAPY IN SOFT TISSUE SARCOMA
A.N. Scholten
Favorite
Schoot, Reineke

Princess Máxima Center for Pediatric Oncology
(P 287) AN INTERNATIONAL SURVEY OF PROVIDER PRACTICES REGARDING BONE MARROW SAMPLING VERSUS [18F] FDG PET/CT IN THE DIAGNOSTIC EVALUATION OF BONE MARROW METASTASIS IN PEDIATRIC RHABDOMYOSARCOMA
Reineke Schoot
Favorite
Schrage, Yvonne

Netherland Cancer Institute
(P 24) NEOADJUVANT CHEMOTHERAPY FOR RADIOTHERAPY ASSOCIATED ANGIOSARCOMA (RAAS) OF THE BREAST IMPROVES ONCOLOGICAL OUTCOMES
Yvonne Schrage
Favorite
(P 28) THE INFLUENCE OF MARGINS ON OUTCOME IN CUTANEOUS LOCATED SOFT TISSUE SARCOMAS IN THE HEAD AND NECK
Yvonne Schrage
Favorite
(P 317) SMARCB1-DEFICIENT SARCOMA OF THE GENITAL REGION/EPITHELIOID SARCOMA OF THE PROXIMAL TYPE VS EPITHELIOID SARCOMA OF THE DISTAL TYPE
Yvonne Schrage
Favorite
(P 378) INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG
Yvonne Schrage
Favorite
Schraw, Jeremy

Baylor College of Medicine
(P 315) SALVAGE THERAPY EFFICACY IS MODIFIED BY RISK GROUP AT DIAGNOSIS IN PATIENTS WITH RELAPSED RHABDOMYOSARCOMA
Jeremy Schraw
Favorite
Schremp, Emma

Vanderbilt University Medical Center
(P 199) FINANCIAL TOXICITY AMONG SARCOMA PATIENTS AND ASSOCIATED FACTORS
Emma Schremp
Favorite
(P 297) ESTABLISHING A PEDIATRIC, ADOLESCENT AND YOUNG ADULT COHORT OF SARCOMA PATIENTS TO STUDY ONCOLOGIC AND NON-ONCOLOGIC OUTCOMES
Emma Schremp
Favorite
Schreuder, Hendrik

Princess Máxima Center for pediatric oncology
(P 319) THE SURVIVAL DISPARITY BETWEEN CHILDREN AND ADOLESCENTS & YOUNG ADULTS WITH EWING SARCOMA IN THE NETHERLANDS DID NOT CHANGE SINCE THE 1990S DESPITE IMPROVED SURVIVAL: A POPULATION-BASED STUDY
Hendrik Schreuder
Favorite
Schreuder, Pim

Netherlands cancer institute
(P 28) THE INFLUENCE OF MARGINS ON OUTCOME IN CUTANEOUS LOCATED SOFT TISSUE SARCOMAS IN THE HEAD AND NECK
Pim Schreuder
Favorite
Schreuder, Willem

Antoni van Leeuwenhoek / Netherlands Cancer Institute
(P 42) RANKL-INHIBITION FOR GIANT CELL LESIONS OF THE JAW: A RETROSPECTIVE COHORT ANALYSIS
Willem Schreuder
Favorite
Schuebbe, Gesa

Department of Medicine III, LMU University Hospital, LMU Munich
(P 410) PHASE I STUDY OF THE001 (DPPG2-TSL-DOX) COMBINED WITH REGIONAL HYPERTHERMIA IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
Gesa Schuebbe
Favorite
Schuetze, Scott

University of Michigan
(P 45) UTILIZATION OF MENTAL HEALTH AND SUPPORTIVE CARE RESOURCES AMONG PATIENTS WITH DESMOID TUMORS
Scott Schuetze
Favorite
(P 102) ANALYSIS OF BLOOD-BASED BIOMARKERS AS PROGNOSTIC FACTORS IN PATIENTS WITH EHE TREATED WITH TRAMETINIB IN SARC033
Scott Schuetze
Favorite
(P 202) IMPACT OF AFAMI-CEL ON THE HEALTH STATE OF PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR MYXOID/ROUND CELL LIPOSARCOMA: COHORT 1 OF SPEARHEAD-1
Scott Schuetze
Favorite
(P 308) PALLIATIVE CARE INVOLVEMENT FOR ADOLESCENTS AND YOUNG ADULTS WITH BONE AND SOFT TISSUE SARCOMAS
Scott Schuetze
Favorite
(P 423) COMPARISON OF CLINICAL COURSE AND FEATURES BETWEEN SCLEROSING EPITHELOID FIBROSARCOMA AND LOW-GRADE FIBROMYXOID SARCOMA
Scott Schuetze
Favorite
Schulpen, Maya

Princess Máxima Center for pediatric oncology
(P 319) THE SURVIVAL DISPARITY BETWEEN CHILDREN AND ADOLESCENTS & YOUNG ADULTS WITH EWING SARCOMA IN THE NETHERLANDS DID NOT CHANGE SINCE THE 1990S DESPITE IMPROVED SURVIVAL: A POPULATION-BASED STUDY
Maya Schulpen
Favorite
Schuster, Kathrin

Sarcoma Patient Advocacy Global Network (SPAGN)
(P 201) GLOBAL CROSS-SECTIONAL SURVEY ON SARCOMA DIAGNOSIS PATHWAY: A CURRENT STATE ANALYSIS
Kathrin Schuster
Favorite
Schwartz, Gary

Case Comprehensive Cancer Center
(P 413) SUSTAINED EFFICACY DURING DRUG HOLIDAY ON ATEZOLIZUMAB IN PATIENTS WITH ALVEOLAR SOFT PART SARCOMA (ASPS)
Gary Schwartz
Favorite
Schwartz, Herbert

Vanderbilt University Medical Center
(P 73) LONGER TIME INTERVAL BETWEEN NEOADJUVANT CHEMOTHERAPY AND SURGERY IS ASSOCIATED WITH DECREASED TUMOR PERCENT NECROSIS IN OSTEOSARCOMA
Herbert Schwartz
Favorite
(P 199) FINANCIAL TOXICITY AMONG SARCOMA PATIENTS AND ASSOCIATED FACTORS
Herbert Schwartz
Favorite
(P 264) INTRAOPERATIVE FROZEN BONE MARROW MARGINS: A HELP OR A HINDRANCE IN EWING SARCOMA RESECTION?
Herbert Schwartz
Favorite
(P 265) IS THERE AN IDEAL STEM TO CANAL RATIO IN LOWER EXTREMITY ONCOLOGIC ENDOPROSTHESIS RECONSTRUCTION?
Herbert Schwartz
Favorite
(P 268) LOWER TUMOR PERCENT NECROSIS IS ASSOCIATED WITH POSITIVE FINAL SURGICAL MARGINS IN OSTEOSARCOMA
Herbert Schwartz
Favorite
(P 297) ESTABLISHING A PEDIATRIC, ADOLESCENT AND YOUNG ADULT COHORT OF SARCOMA PATIENTS TO STUDY ONCOLOGIC AND NON-ONCOLOGIC OUTCOMES
Herbert Schwartz
Favorite
(P 404) ENHANCED RECOVERY AFTER SURGERY (ERAS) PROTOCOL FOR PATENTS WITH SOFT TISSUE SARCOMA OF THE EXTREMITY: A PROSPECTIVE, NON-RANDOMIZED, CONSECUTIVELY ENROLLED TRIAL
Herbert Schwartz
Favorite
Sciortino, Carolina

Fondazione IRCSS Istituto Nazionale dei Tumori
(P 171) GASTROINTESTINAL STROMAL TUMOURS (GISTS) IN NEUROFIBROMATOSIS TYPE (NF1): A SINGLE-CENTER OBSERVATIONAL RETROSPECTIVE STUDY
Carolina Sciortino
Favorite
Sciot, Raf

Department of Pathology, University Hospitals Leuven, Leuven Cancer Institute, Leuven
(P 291) CASE REPORT: RADICAL EN BLOC MULTI-LEVEL SPONDYLECTOMY FOR A LOCALLY RECURRENT OSTEOSARCOMA
Raf Sciot
Favorite
(P 334) EXPANDING THE LANDSCAPE OF PRECLINICAL MODELS OF SYNOVIAL SARCOMA: FROM 2-DIMENSIONS TO 3-DIMENSIONS TO MICE
Raf Sciot
Favorite
SCOAZEC, Jean-yves

Gustave Roussy
(P 53) CHARACTERIZING THE SPATIAL TRANSCRIPTOMIC LANDSCAPE OF OSTEOSARCOMA FROM DIAGNOSIS TO RELAPSE
Jean-yves SCOAZEC
Favorite
Scorianz, Maurizio

University Hospital Careggi, Florence, Italy
(P 274) PROXIMAL HUMERAL ENDOPROSTHETIC RECONSTRUCTION: RESULTS FROM THE MUTARS ORTHOPEDIC REGISTRY EUROPE (MORE)
Maurizio Scorianz
Favorite
Scorsetti, Marta

IRCCS, Humanitas Research Hospital
(P 155) PRIMARY MESENCHYMAL TUMORS OF THE HEART: A 8-YEARS, SINGLE INSTITUTION EXPERIENCE
Marta Scorsetti
Favorite
Scotlandi, Katia

IRCCS Istituto Orthopedico Rizzoli
(P 86) RESPONSE TO MIFAMURTIDE AND TUMOR MICROENVIRONMENT: A DECONVOLUTION NANOSTRING ANALYSIS IN LOCALIZED OSTEOSARCOMA PATIENTS TREATED WITHIN THE ISG/OS2 CLINICAL TRIAL
Katia Scotlandi
Favorite
Scott, Clare

Walter and Eliza Hall Institute of Medical Research
(P 325) CAN PROTEOMICS PREDICT METASTATIC RELAPSE IN LEIOMYOSARCOMA? DEVELOPMENT OF AN 8 PROTEIN SIGNATURE IN A >350 SAMPLE STUDY INCLUDING A VALIDATION COHORT
Clare Scott
Favorite
Scott, Jacob

Cleveland Clinic
(P 351) OSTEOSARCOMA STEREOTACTIC BODY RADIOTHERAPY: OUTCOMES AND PATTERN OF FAILURE
Jacob Scott
Favorite
Scott, Susan

SpringWorks Therapeutics
(P 34) DESMOID TUMOR COHORT CREATION AND CHARACTERISTICS IN THE VETERANS AFFAIRS (VA) NATIONAL DATABASE
Susan Scott
Favorite
Sebio, Ana

Hospital de la Santa Creu i Sant Pau
(P 110) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF PLEOMORPHIC RHABDOMYOSARCOMA (P-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Ana Sebio
Favorite
(P 111) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA (S-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Ana Sebio
Favorite
(P 234) IMMUNOSARC II MASTER TRIAL (PHASE II OF SUNITINIB AND NIVOLUMAB): RESULTS FROM THE CLEAR CELL SARCOMA (CCS) COHORT. A GEIS, ISG, AND UCL STUDY
Ana Sebio
Favorite
Seerat, Maaz

Midland Regional Hospital Portlaoise
(P 310) PROGNOSTICATION AND EPIDEMIOLOGY OF CLEAR CELL SARCOMA: A SEER STAT RETROSPECTIVE ANALYSIS
Maaz Seerat
Favorite
Seffar, Evan

Memorial Sloan Kettering Cancer Center
(P 129) ELUCIDATING THE EVOLUTIONARY DYNAMICS OF DDLS LIPOSARCOMA USING SINGLE-CELL SEQUENCING AND MATHEMATICAL LINEAGE TRACING
Evan Seffar
Favorite
Segers, Blair

Children's Hospital of Philadelphia
(P 318) SYNOVIAL SARCOMA REGISTRY AND BIOSPECIMEN REPOSITORY: DESCRIBING THE COHORT AND SURVIVAL OUTCOMES TO DATE
Blair Segers
Favorite
Sehouli, Jalid

Charité
(P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS
Jalid Sehouli
Favorite
Seibel, Nita Louise

Children's National Hospital
(P 50) ANALYSIS OF CLINICAL FEATURES AND OUTCOMES FOR PATIENTS WITH MULTIFOCAL OSTEOSARCOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Nita Louise Seibel
Favorite
Seidel, Kristy

Seattle Children's Research Institute
(P 226) EARLY EXPERIENCE ON ENLIGHTEN-01: A PHASE 1 STUDY OF BISPECIFIC ADAPTER MOLECULE- CONTROLLED FOLATE RECEPTOR CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY OSTEOSARCOMA
Kristy Seidel
Favorite
Selby, Luke

University of Kansas
(P 36) EARLY REAL-WORLD EXPERIENCE WITH THE USE OF NIROGACESTAT FOR THE TREATMENT OF DESMOID FIBROMATOSIS
Luke Selby
Favorite
Seligson, Nathan

University of Florida
(P 109) INTEGRATED TRANSCRIPTOMIC ANALYSIS OF CIC::DUX4 FUSION SARCOMAS REVEALS ELEVATED PROLIFERATION SIGNALING AND IMPLICATES DNA REPAIR GENE POLE
Nathan Seligson
Favorite
Sellevold, simen

Oslo University Hospital
(P 274) PROXIMAL HUMERAL ENDOPROSTHETIC RECONSTRUCTION: RESULTS FROM THE MUTARS ORTHOPEDIC REGISTRY EUROPE (MORE)
simen Sellevold
Favorite
Sems, Stephen

Mayo Clinic
(P 278) ROTATIONPLASTY AS AN EFFECTIVE LIMB SALVAGE OPTION IN THE ADULT POPULATION
Stephen Sems
Favorite
Senger, Donna

McGill University
(P 329) DEVELOPING ARMS METASTATIC MODELS TO RECAPITULATE THE TUMOR MICROENVIRONMENTS OF THE AXILLA/LYMPH NODE AND LUNGS
Donna Senger
Favorite
Senne, Lane

Inhibrx, Inc
(P 95) THE TETRAVALENT DEATH RECEPTOR 5 AGONIST OZEKIBART (INBRX-109) IN PATIENTS WITH CHONDROSARCOMA: UPDATED RESULTS FROM A PHASE 1 STUDY
Lane Senne
Favorite
Seo, Chin Jin

Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore
(P 370) DEFYING NORMS - CENTRALIZATION OF SARCOMA CARE ON AN ISLAND NATION
Chin Jin Seo
Favorite
(P 375) FROM SAPLING TO SHADE: GROWTH OF A HIGH VOLUME ASIAN TERTIARY SARCOMA SPECIALISED CENTRE
Chin Jin Seo
Favorite
Seo, Sung Wook

Samsung Medical Center
(P 127) DEDIFFERENTIATED LIPOSARCOMA OF THE EXTREMITIES: A KOREAN MULTI-CENTER STUDY OF 107 CASES
Sung Wook Seo
Favorite
Serafini, Arianna

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 110) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF PLEOMORPHIC RHABDOMYOSARCOMA (P-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Arianna Serafini
Favorite
Serafini, Arianna

Fondazione IRCCS Istituto Nazionale dei Tumor
(P 111) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA (S-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Arianna Serafini
Favorite
serra, annalisa

BAMBINO GESU CHILDREN HOSPITAL
(P 298) EWING SARCOMA OF MAXILLOFACIAL REGION AND SKULL: A RETROSPECTIVE MONOINSTITUTIONAL PEDIATRIC SERIES
annalisa serra
Favorite
Serra, Massimo

IRCCS Istituto Ortopedico Rizzoli
(P 86) RESPONSE TO MIFAMURTIDE AND TUMOR MICROENVIRONMENT: A DECONVOLUTION NANOSTRING ANALYSIS IN LOCALIZED OSTEOSARCOMA PATIENTS TREATED WITHIN THE ISG/OS2 CLINICAL TRIAL
Massimo Serra
Favorite
Serrano, César

Vall d’Hebron Institute of Oncology
(P 43) SAFETY AND EFFICACY WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY
César Serrano
Favorite
(P 224) COMPREHENSIVE EVALUATION OF DNA DAMAGE RESPONSE PATHWAY ALTERATIONS AND ASSOCIATED IMMUNOTHERAPY-RESPONSE BIOMARKERS IN SARCOMAS
César Serrano
Favorite
(P 408) OSTEOMYC: A PHASE 2 PILOT STUDY TO EVALIATE THE SAFETY AND THE ANTITUMOR ACTIVITY OF THE MYC INHIBITOR OMO-103 ADMINISTERED INTRAVENOUSLY IN PATIENTS WITH ADVANCED HIGH GRADE OSTEOSARCOMA
César Serrano
Favorite
Setola, Elisabetta

Istituto Europeo di Oncologia
(P 415) TRABECTEDIN PLUS OLAPARIB IN ADVANCED LEIOMYOSARCOMA PROGRESSING AFTER STANDARD TREATMENTS FOR ADVANCED DISEASE: A POOLED ANALYSIS OF TOMAS AND TOMAS2 STUDIES FROM THE ITALIAN SARCOMA GROUP.
Elisabetta Setola
Favorite
Setsu, Nokitaka

Kyushu Cancer Center
(P 203) IMPACT OF COVID-19 PANDEMIC ON BONE AND SOFT TISSUE SARCOMA PATIENTS' CONSULTATION AND DIAGNOSIS
Nokitaka Setsu
Favorite
Setty, Bhuvana

Nationwide Children's Hospital
(P 309) PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT SOFT TISSUE SARCOMA: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Bhuvana Setty
Favorite
(P 315) SALVAGE THERAPY EFFICACY IS MODIFIED BY RISK GROUP AT DIAGNOSIS IN PATIENTS WITH RELAPSED RHABDOMYOSARCOMA
Bhuvana Setty
Favorite
Seung, Soo Jin

HOPE Research Centre
(P 135) SURVIVAL OUTCOMES AND TREATMENT PATTERNS FOR PATIENTS WITH DEDIFFERENTIATED LIPOSARCOMA: A RETROSPECTIVE COHORT STUDY IN ONTARIO, CANADA
Soo Jin Seung
Favorite
Severe, Nicolas

Pyxis Oncology
(P 339) SARCOMAS EXPRESS EXTRA DOMAIN B OF FIBRONECTIN AND PRECLINICAL PATIENT-DERIVED XENOGRAFT MODELS OF SEVERAL SARCOMA SUBTYPES ARE SENSITIVE TO THE STROMA TARGETING ANTIBODY DRUG CONJUGATE PYX-201
Nicolas Severe
Favorite
Shaberman, Amy

Boehringer Ingelheim Pharmaceuticals, Inc
(P 206) PATIENT PERSPECTIVE ON LIPOSARCOMA DIAGNOSTIC JOURNEY: INTERIM PATIENT SURVEY RESULTS
Amy Shaberman
Favorite
Shafer, Amanda

University of Michigan
(P 131) HETEROGENEITY OF THE IMMUNE MICROENVIRONMENT AND IMMUNOTHERAPY RESPONSE IN A DEDIFFERENTIATED LIPOSARCOMA MOUSE MODEL
Amanda Shafer
Favorite
(P 341) THE EFFECTS OF ULTRASOUND-GUIDED HISTOTRIPSY ON SOFT TISSUE SARCOMA
Amanda Shafer
Favorite
(P 423) COMPARISON OF CLINICAL COURSE AND FEATURES BETWEEN SCLEROSING EPITHELOID FIBROSARCOMA AND LOW-GRADE FIBROMYXOID SARCOMA
Amanda Shafer
Favorite
Shaha, Priyanshu

St. George’s Hospital, London
(P 261) EVALUATION OF CT ARTIFACTS AFTER SPINAL OLIGOMETASTATIC DISEASE RESECTION AND RECONSTRUCTION: A COMPARATIVE STUDY OF CARBON-FIBER VS. TITANIUM IMPLANTS
Priyanshu Shaha
Favorite
Shah, Rachana

Children's Hospital Los Angeles
(P 76) MOLECULAR AND CHROMOSOMAL MICROARRAY PROFILING OF OSTEOSARCOMA IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS: A SINGLE INSTITUTION REPORT
Rachana Shah
Favorite
Sha, Matthew

School of Nursing, University of British Columbia
(P 201) GLOBAL CROSS-SECTIONAL SURVEY ON SARCOMA DIAGNOSIS PATHWAY: A CURRENT STATE ANALYSIS
Matthew Sha
Favorite
Shams, Danial

Vanderbilt University Medical Center
(P 404) ENHANCED RECOVERY AFTER SURGERY (ERAS) PROTOCOL FOR PATENTS WITH SOFT TISSUE SARCOMA OF THE EXTREMITY: A PROSPECTIVE, NON-RANDOMIZED, CONSECUTIVELY ENROLLED TRIAL
Danial Shams
Favorite
Shan, Boyao

Abbisko Therapeutics Co., Ltd
(P 407) LONG-TERM EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): PHASE 1B UPDATE.
Boyao Shan
Favorite
Shapiro, David

University of Illinois Urbana-Champaign
(P 79) NOVEL THERAPEUTIC POTENTIAL THROUGH HYPERACTIVATION OF THE ANTICIPATORY UNFOLDED PROTEIN RESPONSE PATHWAY IN BONE CANCER TREATMENT
David Shapiro
Favorite
Shapiro, Geoffrey

Dana-Farber Cancer Institute, Ludwig Center at Harvard Medical School
(P 47) A PHASE 2 STUDY OF OLAPARIB IN METASTATIC IDH1 AND IDH2 MUTANT CHONDROSARCOMAS
Geoffrey Shapiro
Favorite
(P 402) A PILOT STUDY OF BTX-A51 IN PATIENTS WITH METASTATIC AND/OR RECURRENT LIPOSARCOMAS CHARACTERIZED BY MDM2 AMPLIFICATIONS
Geoffrey Shapiro
Favorite
Shapiro, Joel

The Princess Margaret/Mount Sinai Hospital
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
Joel Shapiro
Favorite
Sharib, Jeremy

University of Washington
(P 378) INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG
Jeremy Sharib
Favorite
Sharma, Ashwyn

University of California, San Diego
(P 165) COMPLETE PERITONEAL CYTOREDUCTIVE SURGERY IN HIGHLY SELECTED PATIENTS WITH AGGRESSIVE METASTATIC SDH-DEFICIENT GIST CAN PROLONG EVENT-FREE SURVIVAL
Ashwyn Sharma
Favorite
Sharma, Ayush

Sarcoma Oncology Center
(P 250) UPDATE ON GALLANT: A PHASE 2 STUDY USING METRONOMIC GEMCITABINE, DOXORUBICIN AND DOCETAXEL PLUS NIVOLUMAB IN PREVIOUSLY TREATED SARCOMA (NCT04535713)
Ayush Sharma
Favorite
Sharma, Maitreyi

Deciphera Pharmaceuticals, LLC
(P 43) SAFETY AND EFFICACY WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY
Maitreyi Sharma
Favorite
Sharon, Elad

Dana-Farber Cancer Institute
(P 413) SUSTAINED EFFICACY DURING DRUG HOLIDAY ON ATEZOLIZUMAB IN PATIENTS WITH ALVEOLAR SOFT PART SARCOMA (ASPS)
Elad Sharon
Favorite
Sharp, Delaney

Princess Margaret Cancer Centre
(P 321) WHOLE ABDOMINAL RADIOTHERAPY IN CHILDREN AND YOUNG ADULTS WITH SARCOMA: A CANADIAN SARCOMA AND CLINICAL COLLABORATION (CANSARCC) STUDY
Delaney Sharp
Favorite
Shaulov Kask, Angela

Fred Hutchinson Cancer Center
(P 222) ANALYSIS OF THE CITN-13 SARCOMA ARM: PEMBROLIZUMAB AND INTERFERON GAMMA FOR SYNOVIAL SARCOMA AND MYXOID/ ROUND CELL LIPOSARCOMA
Angela Shaulov Kask
Favorite
Sheel, Ankur

The Ohio State University
(P 328) DETERMINING BIOMARKERS FOR GEMCITABINE RESPONSE IN SOFT TISSUE SARCOMAS: LESSONS LEARNED FROM PANCREATIC CANCER
Ankur Sheel
Favorite
Shemla, Shanie

Memorial Sloan Kettering Cancer Center
(P 101) AN OPEN LABEL PHASE IIA STUDY EVALUATING THE PRELIMINARY EFFICACY OF INTRATUMORAL TIGILANOL TIGLATE (TT) IN ADVANCED AND/OR METASTATIC SOFT TISSUE SARCOMA (STS, NCT05755113)
Shanie Shemla
Favorite
Shen, Guoxiang George

ADC Therapeutics
(P 116) QUANTITATIVE SYSTEMS PHARMACOLOGY MODELING OF MIPASETAMAB UZOPTERINE INTEGRATES KNOWLEDGE AND DEFINES DOSING STRATEGY FOR PATIENTS WITH SARCOMA
Guoxiang George Shen
Favorite
Shen, Jiakang

Department of Orthopedic Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai Bone Tumor Institution, Shanghai, China
(P 48) A SINGLE-ARM, OPEN-LABEL CLINICAL STUDY OF OVV-01 ONCOLYTIC VIRUS INJECTION AS MONOTHERAPY OR IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS FOR ADVANCED SOLID TUMOR PATIENTS
Jiakang Shen
Favorite
Shen, Jingnan

Department of Musculoskeletal Oncology Center, The First Affiliated Hospital of Sun Yat-sen University
(P 407) LONG-TERM EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): PHASE 1B UPDATE.
Jingnan Shen
Favorite
Shen, Jing-Nan

The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
(P 132) PATIENT CHARACTERISTICS, TREATMENT PATTERNS AND DISEASE BURDEN OF DEDIFFERENTIATED LIPOSARCOMA IN CHINA: A REAL-WORLD STUDY BASED ON NATIONAL CANCER REGISTRY
Jing-Nan Shen
Favorite
Shen, Lin

Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute
(P 180) TUMOR VASCULAR SIGN IN THE RESPONSE ASSESSMENT OF GASTROINTESTINAL STROMAL TUMOR TREATED WITH RIPRETINIB: A MULTICENTER STUDY
Lin Shen
Favorite
(P 396) LONG-TERM FOLLOW-UP EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
Lin Shen
Favorite
Shepard, Dale

Cleveland Clinic
(P 403) DCC-3116 IN COMBINATION WITH RIPRETINIB FOR PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR: A PHASE 1/2 STUDY
Dale Shepard
Favorite
Sheppard, Brett

OHSU
(P 364) A PHASE 1B TRIAL OF PREOPERATIVE ERIBULIN AND RADIATION FOR RETROPERITONEAL LIPOSARCOMA
Brett Sheppard
Favorite
Sheppard, Heather

St. Jude Children’s Research Hospital
(P 288) ANGIOA: A SAFETY AND TOLERABILITY STUDY OF TRIPLE ANTI-ANGIOGENIC THERAPY COMBINED WITH PD-L1 BLOCKADE IN PEDIATRIC, ADOLESCENT AND YOUNG ADULT RECURRENT/REFRACTORY SOLID TUMORS
Heather Sheppard
Favorite
Sheppard, Joanna

University College London Hospital
(P 185) ADDRESSING THE GAP FOR SYMPTOM CONTROL THROUGH THE IMPLEMENTATION OF ENHANCED SUPPORTIVE CARE AT THE LONDON SARCOMA SERVICE
Joanna Sheppard
Favorite
Sherman, John

Nationwide Children's Hospital
(P 21) LSD1 INHIBITOR SP-2509 DISRUPTS IRON-SULFUR CLUSTER BIOGENESIS
John Sherman
Favorite
Sherman, Matthew

Deciphera Pharmaceuticals, LLC
(P 43) SAFETY AND EFFICACY WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY
Matthew Sherman
Favorite
(P 181) UPDATED OVERALL SURVIVAL WITH RIPRETINIB VS SUNITINIB IN PATIENTS WITH SECOND-LINE ADVANCED GASTROINTESTINAL STROMAL TUMOR AND KIT EXON 11+17/18 MUTATIONS: CIRCULATING TUMOR DNA ANALYSIS FROM INTRIGUE
Matthew Sherman
Favorite
(P 403) DCC-3116 IN COMBINATION WITH RIPRETINIB FOR PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR: A PHASE 1/2 STUDY
Matthew Sherman
Favorite
Shi, Haosong

Abbisko Therapeutics Co., Ltd.
(P 407) LONG-TERM EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): PHASE 1B UPDATE.
Haosong Shi
Favorite
Shimada, Eijiro

Duke University
(P 15) HISTONE DEACETYLASE-3 PLAYS A ROLE IN THE METASTATIC POTENTIAL OF A SUBPOPULATION OF CELLS IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Eijiro Shimada
Favorite
(P 203) IMPACT OF COVID-19 PANDEMIC ON BONE AND SOFT TISSUE SARCOMA PATIENTS' CONSULTATION AND DIAGNOSIS
Eijiro Shimada
Favorite
Shinan-Altman, Shiri

School of Social Work, Bar Ilan University, Ramat Gan Israel
(P 182) A NOVEL MODEL FOR THE DIRECT REFERRAL OF ONCOLOGIC PATIENTS IN A PUBLIC HEALTH CARE SYSTEM
Shiri Shinan-Altman
Favorite
Shinglot, Himaly

Northwestern University, Feinberg School of Medicine
(P 222) ANALYSIS OF THE CITN-13 SARCOMA ARM: PEMBROLIZUMAB AND INTERFERON GAMMA FOR SYNOVIAL SARCOMA AND MYXOID/ ROUND CELL LIPOSARCOMA
Himaly Shinglot
Favorite
(P 235) INFILTRATION OF MUCOSAL-ASSOCIATED INVARIANT T CELLS (MAITS) INTO CHONDROSARCOMA TUMORS
Himaly Shinglot
Favorite
Shinoda, Yasuo

Department of Urology, National Cancer Center Hospital, Tokyo, Japan
(P 134) REAL-WORLD CLINICAL OUTCOME OF NEOADJUVANT CHEMOTHERAPY FOR RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA
Yasuo Shinoda
Favorite
Shinohara, Eric

Vanderbilt University Medical Center
(P 199) FINANCIAL TOXICITY AMONG SARCOMA PATIENTS AND ASSOCIATED FACTORS
Eric Shinohara
Favorite
(P 297) ESTABLISHING A PEDIATRIC, ADOLESCENT AND YOUNG ADULT COHORT OF SARCOMA PATIENTS TO STUDY ONCOLOGIC AND NON-ONCOLOGIC OUTCOMES
Eric Shinohara
Favorite
Shinozaki-Ushiku, Aya

The University of Tokyo, Division of Integrative Genomics
(P 103) BRAF MUTATIONS AND CONCURRENT ALTERATIONS IN PATIENTS WITH SOFT TISSUE SARCOMA
Aya Shinozaki-Ushiku
Favorite
Shlien, Adam

The Hospital for Sick Children
(P 49) A WORKING GROUP FOR THE DEVELOPMENT OF A CLINICAL FRAMEWORK THAT STRATIFIES OSTEOSARCOMA PATIENTS USING BIOMARKERS OF CLINICAL RISK AND BIOLOGY
Adam Shlien
Favorite
(P 159) USING THE TRANSCRIPTIONAL SPECTRUM OF UTERINE SMOOTH MUSCLE TUMORS TO IDENTIFY PROGNOSTIC SIGNATURES FOR ABNORMAL LEIOMYOMAS AND SMOOTH MUSCLE TUMOURS OF UNCERTAIN MALIGNANT POTENTIAL
Adam Shlien
Favorite
(P 329) DEVELOPING ARMS METASTATIC MODELS TO RECAPITULATE THE TUMOR MICROENVIRONMENTS OF THE AXILLA/LYMPH NODE AND LUNGS
Adam Shlien
Favorite
Shoaib, Zunaira

University of Illinois Urbana-Champaign
(P 419) BONE MECHANICS INFLUENCE CANCER STEM CELL FORMATION IN OSTEOSARCOMA
Zunaira Shoaib
Favorite
Shoghi, Kooresh

Washington University in St. Louis School of Medicine
(P 145) EXPLORING L-TYPE AMINO ACID TRANSPORTER 1 (LAT1) AS A DIAGNOSTIC MARKER AND THERAPEUTIC TARGET IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST)
Kooresh Shoghi
Favorite
Sholevar, Cyrus

Division of Surgical Oncology, Department of Surgery, University of California Davis
(P 230) HIGHER BODY MASS INDEX IS ASSOCIATED WITH DECREASED CIRCULATING AND INTRATUMORAL NATURAL KILLER CELLS IN SOFT TISSUE SARCOMA
Cyrus Sholevar
Favorite
Shulman, David

Dana-Farber Cancer Institute
(P 49) A WORKING GROUP FOR THE DEVELOPMENT OF A CLINICAL FRAMEWORK THAT STRATIFIES OSTEOSARCOMA PATIENTS USING BIOMARKERS OF CLINICAL RISK AND BIOLOGY
David Shulman
Favorite
Shultz, David

Princess Margaret Cancer Centre, University Health Network
(P 352) OUTCOMES OF PRIMARY INTRATHORACIC SOFT TISSUE SARCOMA
David Shultz
Favorite
(P 433) TUMOR HYPOXIA AND THE RISK OF METASTASIS IN HIGH-RISK LOCALIZED UPS/MFS
David Shultz
Favorite
Shu, Xiao-Ou

Vanderbilt University Medical Center
(P 199) FINANCIAL TOXICITY AMONG SARCOMA PATIENTS AND ASSOCIATED FACTORS
Xiao-Ou Shu
Favorite
(P 297) ESTABLISHING A PEDIATRIC, ADOLESCENT AND YOUNG ADULT COHORT OF SARCOMA PATIENTS TO STUDY ONCOLOGIC AND NON-ONCOLOGIC OUTCOMES
Xiao-Ou Shu
Favorite
Sicklick, Jason

University of California, San Diego
(P 162) ANALYSIS OF 3,144 CASE REPORTS IN THE GASTROINTESTINAL STROMAL TUMOR LITERATURE: IDENTIFICATION OF UNDERAPPRECIATED DEMOGRAPHICS, CLINICAL PRESENTATIONS, AND BIOLOGY
Jason Sicklick
Favorite
(P 165) COMPLETE PERITONEAL CYTOREDUCTIVE SURGERY IN HIGHLY SELECTED PATIENTS WITH AGGRESSIVE METASTATIC SDH-DEFICIENT GIST CAN PROLONG EVENT-FREE SURVIVAL
Jason Sicklick
Favorite
(P 167) DEFINING TEXTBOOK OUTCOMES FOR MINIMALLY INVASIVE SURGICAL RESECTION OF SMALL GASTROINTESTINAL STROMAL TUMORS (GIST) OF THE STOMACH
Jason Sicklick
Favorite
(P 175) KIT AND DOG-1 EXPRESSING GASTROINTESTINAL STROMAL TUMORS HARBORING ETV6-NTRK3 FUSIONS DO EXIST, CASE OF NEAR COMPLETE PATHOLOGIC RESPONSE FOLLOWING LAROTRECTINIB AND REVIEW OF THE LITERATURE
Jason Sicklick
Favorite
(P 246) THE GENOMIC AND IMMUNE LANDSCAPE OF LIPOSARCOMA AND ITS SUBTYPES
Jason Sicklick
Favorite
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
Jason Sicklick
Favorite
Sicoli, Federico

IRCCS Humanitas Research Hospital
(P 362) A NEW ROCK BAND FOR DIAPHRAGMATIC RECONSTRUCTION IN LEFT RETROPERITONEAL SARCOMA SURGERY
Federico Sicoli
Favorite
(P 363) A NEW SURGICAL TECHNIQUE FOR THE RECONSTRUCTION OF INGUINAL 'NEOLIGAMENT' AFTER SOFT TISSUE SARCOMA RESECTION
Federico Sicoli
Favorite
(P 373) EVALUATION OF HISTOLOGIC ORGAN INFILTRATION (HOI) AND VISCERAL RESECTION MARGINS (VRM) IN PRIMARY RETROPERITONEAL SARCOMAS: PROGNOSTIC IMPLICATIONS FOR LOCAL RECURRENCE
Federico Sicoli
Favorite
(P 388) THE ROAD TO CURATIVE SURGERY IN RETROPERITONEAL SOFT TISSUE SARCOMA: A DIFFERENT PATH IN THE ELDERLY?
Federico Sicoli
Favorite
(P 389) THE ROLE OF NUTRITIONAL STATUS ON POSTOPERATIVE AND ONCOLOGICAL OUTCOMES IN RETROPERITONEAL SARCOMA
Federico Sicoli
Favorite
Sida, Deseray

University of Texas Southwestern Medical Center
(P 417) VITAS: ATEZOLIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR PEDIATRIC RELAPSED/REFRACTORY SOLID TUMORS: AN OPEN-LABEL, PHASE I/II, SINGLE-ARM, MULTI-CENTER TRIAL IN PROGRESS
Deseray Sida
Favorite
Siddiquee, Armaan

Memorial Sloan Kettering Cancer Center
(P 338) PRECLINICAL EFFICACY OF DAN-222, A NOVEL POLYMERIC NANOPARTICLE, IN PEDIATRIC SOLID TUMOR MODELS
Armaan Siddiquee
Favorite
Siddiqui, Maryam

Lunenfeld-Tanenbaum Research Institute
(P 329) DEVELOPING ARMS METASTATIC MODELS TO RECAPITULATE THE TUMOR MICROENVIRONMENTS OF THE AXILLA/LYMPH NODE AND LUNGS
Maryam Siddiqui
Favorite
Siegel, Geoffrey

University of Michigan Department of Orthopedic Surgery
(P 341) THE EFFECTS OF ULTRASOUND-GUIDED HISTOTRIPSY ON SOFT TISSUE SARCOMA
Geoffrey Siegel
Favorite
SIGNOLLE, Nicolas

Gustave Roussy
(P 53) CHARACTERIZING THE SPATIAL TRANSCRIPTOMIC LANDSCAPE OF OSTEOSARCOMA FROM DIAGNOSIS TO RELAPSE
Nicolas SIGNOLLE
Favorite
Silberman, Allan

Cedars-Sinai Medical Center
(P 140) CIRCULATING TUMOR DNA AS A TOOL OF SURVEILLANCE AND EARLY INDICATOR OF RELAPSE IN SARCOMA PATIENTS
Allan Silberman
Favorite
Silletta, Marianna

Fondazione Policlinico Campus Bio-Medico of Rome
(P 178) PREDICTION OF PRIMARY IMATINIB-REFRACTORY PATIENTS WITH LOCALLY ADVANCED OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) USING RADIOMICS AND ARTIFICIAL INTELLIGENCE (AI)
Marianna Silletta
Favorite
Silvia, Careri

Ospedale Pediatrico Bambino Gesù
(P 311) QUANTIFICATION OF TUMOUR-INFILTRATING IMMUNE CELLS THROUGH DECONVOLUTION OF DNA METHYLATION DATA IN EWING SARCOMAS
Careri Silvia
Favorite
Sindiri, Sivasish

Surgery Branch, NCI, NIH
(P 231) IDENTIFICATION OF NEOANTIGEN FROM PECOMA-LIKE NEOPLASM PROVIDES RATIONALE FOR TREATMENT WITH CELLULAR THERAPY
Sivasish Sindiri
Favorite
Singer, Ramsay

The Royal Marsden Hospital
(P 183) A RETROSPECTIVE STUDY OF THE EFFECTS OF PATIENT, DISEASE, AND TREATMENT FACTORS ON SURVIVAL OUTCOMES IN PATIENTS WITH SOFT TISSUE SARCOMA BRAIN METASTASES
Ramsay Singer
Favorite
Singer, Samuel

Memorial Sloan Kettering Cancer Center
(P 101) AN OPEN LABEL PHASE IIA STUDY EVALUATING THE PRELIMINARY EFFICACY OF INTRATUMORAL TIGILANOL TIGLATE (TT) IN ADVANCED AND/OR METASTATIC SOFT TISSUE SARCOMA (STS, NCT05755113)
Samuel Singer
Favorite
(P 121) ACQUIRED CYCLIN D AMPLIFICATION IS A MECHANISM FOR RESISTANCE TO CDK4/6 INHIBITORS IN DEDIFFERENTIATED LIPOSARCOMA
Samuel Singer
Favorite
(P 129) ELUCIDATING THE EVOLUTIONARY DYNAMICS OF DDLS LIPOSARCOMA USING SINGLE-CELL SEQUENCING AND MATHEMATICAL LINEAGE TRACING
Samuel Singer
Favorite
(P 229) EXPRESSION OF TRANSPOSABLE ELEMENTS AND IKZF1 PREDICTS IMMUNE INFILTRATES IN SARCOMAS AND CORRELATES WITH OUTCOMES AFTER IMMUNE CHECKPOINT INHIBITION
Samuel Singer
Favorite
(P 380) MULTIDISCIPLINARY MANAGEMENT OF INTRA-ABDOMINAL DESMOID-TYPE FIBROMATOSIS: A 30-YEARS EXPERIENCE
Samuel Singer
Favorite
Singh, Ahilya

ProCan, Children’s Medical Research Institute
(P 325) CAN PROTEOMICS PREDICT METASTATIC RELAPSE IN LEIOMYOSARCOMA? DEVELOPMENT OF AN 8 PROTEIN SIGNATURE IN A >350 SAMPLE STUDY INCLUDING A VALIDATION COHORT
Ahilya Singh
Favorite
Singh, Arun

University of California at Los Angeles
(P 400) A LONG-TERM PHASE 4 STUDY TO EVALUATE THE RISK OF HEPATOTOXICITY ASSOCIATED WITH PEXIDARTINIB TREATMENT
Arun Singh
Favorite
Singh, Reena

Vanderbilt University Medical Center
(P 73) LONGER TIME INTERVAL BETWEEN NEOADJUVANT CHEMOTHERAPY AND SURGERY IS ASSOCIATED WITH DECREASED TUMOR PERCENT NECROSIS IN OSTEOSARCOMA
Reena Singh
Favorite
(P 264) INTRAOPERATIVE FROZEN BONE MARROW MARGINS: A HELP OR A HINDRANCE IN EWING SARCOMA RESECTION?
Reena Singh
Favorite
(P 268) LOWER TUMOR PERCENT NECROSIS IS ASSOCIATED WITH POSITIVE FINAL SURGICAL MARGINS IN OSTEOSARCOMA
Reena Singh
Favorite
Singh-Varma, Anya

University of Pittsburgh School of Medicine
(P 117) THE TUMOR IMMUNE MICROENVIRONMENT OF DEDIFFERENTIATED SARCOMAS: DIGITAL SPATIAL PROFILING SHOWS IMMUNE TRANSCRIPTIONAL DIFFERENCES BETWEEN DEDIFFERENTIATED LIPOSARCOMA AND CHONDROSARCOMA
Anya Singh-Varma
Favorite
Singh, Vinit

Roswell Park Comprehensive Cancer Center
(P 35) EARLY REAL WORLD EXPERIENCE WITH NIROGACESTAT IN PATIENTS WITH DESMOID FIBROMATOSIS
Vinit Singh
Favorite
Singla, Arvind

McCaig Institute for Bone and Joint Health
(P 327) CHARACTERIZATION OF TWO NOVEL IMMUNE COMPETENT, MURINE MODELS OF SOFT TISSUE SARCOMA
Arvind Singla
Favorite
Sinnaeve, Friedl

UZ Leuven
(P 291) CASE REPORT: RADICAL EN BLOC MULTI-LEVEL SPONDYLECTOMY FOR A LOCALLY RECURRENT OSTEOSARCOMA
Friedl Sinnaeve
Favorite
(P 334) EXPANDING THE LANDSCAPE OF PRECLINICAL MODELS OF SYNOVIAL SARCOMA: FROM 2-DIMENSIONS TO 3-DIMENSIONS TO MICE
Friedl Sinnaeve
Favorite
Siontis, Brittany

Mayo Clinic
(P 120) USING AI PREDICTIONS FROM ECG TRACINGS TO PREDICT TOLERANCE TO ANTHRACYCLINE CHEMOTHERAPY IN SARCOMA
Brittany Siontis
Favorite
(P 200) FRAILTY ASSESSMENT IN OLDER PATIENTS RECEIVING SARCOMA THERAPY
Brittany Siontis
Favorite
Sirineni, Pradyoth

The Ohio State University College of Medicine
(P 244) PREDICTIVE VALUE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO IN IMMUNOTHERAPY OUTCOMES IN ADVANCED SARCOMA
Pradyoth Sirineni
Favorite
Siriprabrydhi, Michael

Sarcoma Oncology Center
(P 250) UPDATE ON GALLANT: A PHASE 2 STUDY USING METRONOMIC GEMCITABINE, DOXORUBICIN AND DOCETAXEL PLUS NIVOLUMAB IN PREVIOUSLY TREATED SARCOMA (NCT04535713)
Michael Siriprabrydhi
Favorite
Skeie, Annette Torød

Oslo University Hospital
(P 40) PEGYLATED LIPOSOMAL DOXORUBICIN IN SYMPTOMATIC DESMOID TUMOR
Annette Torød Skeie
Favorite
skoczylas, jacek

Maria Sklodowska-Curie National Research Institute of Oncology
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
jacek skoczylas
Favorite
Skol, Andrew

Ann & Robert H Lurie Children's Hospital of Chicago
(P 04) CHROMOSOME SPECIFIC ORGANIZATIONAL CHARACTERISTICS IN RHABDOMYOSARCOMA AND NORMAL MYOGENIC CELLS
Andrew Skol
Favorite
SKubitz, Keith

University of Minnesota
(P 30) CLINICAL BENEFIT OF PEGYLATED-LIPOSOMAL DOXORUBICIN IN THE MANAGEMENT DESMOID TYPE FIBROMATOSIS: A SINGLE INSTITUTION EXPERIENCE
Keith SKubitz
Favorite
Slotkin, Emily

Memorial Sloan Kettering Cancer Center
(P 229) EXPRESSION OF TRANSPOSABLE ELEMENTS AND IKZF1 PREDICTS IMMUNE INFILTRATES IN SARCOMAS AND CORRELATES WITH OUTCOMES AFTER IMMUNE CHECKPOINT INHIBITION
Emily Slotkin
Favorite
(P 418) A SYSTEMS BIOLOGY APPROACH FOR CHARACTERIZING TUMOR HETEROGENEITY AND CELL STATE-SPECIFIC THERAPEUTIC VULNERABILITIES FROM SINGLE NUCLEUS RNA-SEQ PROFILING OF DESMOPLASTIC SMALL ROUND CELL TUMORS
Emily Slotkin
Favorite
Smith, Ed

The Christie NHS Foundation Trust
(P 60) DIAGNOSIS AND MANAGEMENT OF PAEDIATRIC EWING SARCOMA PATIENTS IN ENGLAND 2014-2017: A COMPARISON OF NATIONAL DATA WITH THE EURO-EWING 2012 CLINICAL TRIAL
Ed Smith
Favorite
Smith-Fry, Kyllie

University of Utah
(P 332) ENHANCING THERAPEUTIC EFFICACY IN SYNOVIAL SARCOMA BY TARGETING P53-MDM2 AXIS AND HDAC PATHWAYS
Kyllie Smith-Fry
Favorite
Smith-Fry, Kyllie

Department of Orthopaedics, University of Utah
(P 343) TLE1 DISRUPTION DOES NOT IMPEDE SYNOVIAL SARCOMAGENESIS
Kyllie Smith-Fry
Favorite
Smrke, Alannah

BC Canada
(P 293) CIC-REARRANGED SOFT TISSUE SARCOMAS: DOES CHEMOTHERAPY CHANGE NATURAL HISTORY AND PROGNOSIS? A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Alannah Smrke
Favorite
(P 320) WHAT IS THE ROLE OF CHEMOTHERAPY IN PATIENTS (PTS) WITH SPINDLE CELL/SCLEROSING RHABDOMYOSARCOMA (SCRMS): A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Alannah Smrke
Favorite
Smythe, Kimberly

FHCRC
(P 222) ANALYSIS OF THE CITN-13 SARCOMA ARM: PEMBROLIZUMAB AND INTERFERON GAMMA FOR SYNOVIAL SARCOMA AND MYXOID/ ROUND CELL LIPOSARCOMA
Kimberly Smythe
Favorite
Snaebjornsson, Petur

Netherlands Cancer Institute
(P 317) SMARCB1-DEFICIENT SARCOMA OF THE GENITAL REGION/EPITHELIOID SARCOMA OF THE PROXIMAL TYPE VS EPITHELIOID SARCOMA OF THE DISTAL TYPE
Petur Snaebjornsson
Favorite
Snow, Hayden

Peter MacCallum Cancer Centre
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
Hayden Snow
Favorite
Snyder, Benjamin

Indiana University School of Medicine
(P 365) A SINGLE INSTITUTION COMPARISON OF OUTCOMES IN PEDIATRIC AND ADULT PATIENTS WITH GYNECOLOGIC ORIGIN RHABDOMYOSARCOMA
Benjamin Snyder
Favorite
(P 384) REAL WORLD EXPERIENCE IN TREATING HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA: AN ULTRA-RARE VASCULAR TUMOR
Benjamin Snyder
Favorite
Sobczuk, Paweł

Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
(P 46) A NEED FOR STANDARDIZATION IN TRIAL DESIGN AND DATA REPORTING IN PHASE II TRIALS IN RARE TUMORS. LESSONS LEARNED FROM PHASE II TRIALS IN BONE SARCOMAS
Paweł Sobczuk
Favorite
(P 245) PRELIMINARY RESULTS FROM A PHASE 2 EFTISARC-NEO TRIAL OF NEOADJUVANT SOUBLE LAG-3 PROTEIN EFTILAGIMOD ALPHA, PEMBROLIZUMAB, AND CONCURRENT RADIOTHERAPY IN PATIENTS WITH RESECTABLE SOFT TISSUE SARCOMA
Paweł Sobczuk
Favorite
Socci, Nicholas

Memorial Sloan Kettering Cancer Center
(P 129) ELUCIDATING THE EVOLUTIONARY DYNAMICS OF DDLS LIPOSARCOMA USING SINGLE-CELL SEQUENCING AND MATHEMATICAL LINEAGE TRACING
Nicholas Socci
Favorite
Soffientini, Cesare

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 137) TARGETING PRIMARY AND SECONDARY ONCOGENIC DRIVERS IN RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMAS
Cesare Soffientini
Favorite
Soh Hann, Natalie

Singapore General Hospital
(P 370) DEFYING NORMS - CENTRALIZATION OF SARCOMA CARE ON AN ISLAND NATION
Natalie Soh Hann
Favorite
Sokol, Elizabeth

Ann & Robert H. Lurie Children's Hospital of Chicago
(P 417) VITAS: ATEZOLIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR PEDIATRIC RELAPSED/REFRACTORY SOLID TUMORS: AN OPEN-LABEL, PHASE I/II, SINGLE-ARM, MULTI-CENTER TRIAL IN PROGRESS
Elizabeth Sokol
Favorite
Solda, Francesca

The Royal Marsden Hospital
(P 183) A RETROSPECTIVE STUDY OF THE EFFECTS OF PATIENT, DISEASE, AND TREATMENT FACTORS ON SURVIVAL OUTCOMES IN PATIENTS WITH SOFT TISSUE SARCOMA BRAIN METASTASES
Francesca Solda
Favorite
Soliman, Steven

University of Michigan / Musculoskeletal Radiology Division
(P 341) THE EFFECTS OF ULTRASOUND-GUIDED HISTOTRIPSY ON SOFT TISSUE SARCOMA
Steven Soliman
Favorite
Solimini, Nicole

Dana-Farber Cancer Institute
(P 402) A PILOT STUDY OF BTX-A51 IN PATIENTS WITH METASTATIC AND/OR RECURRENT LIPOSARCOMAS CHARACTERIZED BY MDM2 AMPLIFICATIONS
Nicole Solimini
Favorite
Solnik, Jonathon

Mount Sinai Hospital
(P 159) USING THE TRANSCRIPTIONAL SPECTRUM OF UTERINE SMOOTH MUSCLE TUMORS TO IDENTIFY PROGNOSTIC SIGNATURES FOR ABNORMAL LEIOMYOMAS AND SMOOTH MUSCLE TUMOURS OF UNCERTAIN MALIGNANT POTENTIAL
Jonathon Solnik
Favorite
Solst, Shane

University of Iowa
(P 12) GENETIC LANDSCAPE OF MPNST DETERMINES METABOLIC STRATEGIES AND THERAPEUTIC OPPORTUNITIES FOR COPING WITH REDOX STRESS
Shane Solst
Favorite
Somaiah, Neeta

The University of Texas MD Anderson Cancer Center
(P 130) HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RESECTABLE RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA (DDLPS) TREATED WITH NEOADJUVANT CHECKPOINT BLOCKADE IN A RANDOMIZED PHASE II CLINICAL TRIAL.
Neeta Somaiah
Favorite
(P 181) UPDATED OVERALL SURVIVAL WITH RIPRETINIB VS SUNITINIB IN PATIENTS WITH SECOND-LINE ADVANCED GASTROINTESTINAL STROMAL TUMOR AND KIT EXON 11+17/18 MUTATIONS: CIRCULATING TUMOR DNA ANALYSIS FROM INTRIGUE
Neeta Somaiah
Favorite
(P 233) IMMUNE CLASSES OF LEIOMYOSARCOMA DRIVEN BY B CELL INFILTRATE AND CTLA4 EXPRESSION
Neeta Somaiah
Favorite
Somarelli, Jason

Duke University
(P 16) HOW TO GROW A BONE IN 60 DAYS: EXPLORING THE UNIQUE PRO-GROWTH, ANTI-CANCER ENVIRONMENT IN ELK ANTLERS
Jason Somarelli
Favorite
Sommer, Josh

Chordoma Foundation
(P 02) A PRECLINICAL ASSAY PIPELINE TO IDENTIFY AND OPTIMIZE BRACHYURY-TARGETED THERAPIES IN CHORDOMA AND OTHER SOLID TUMORS
Josh Sommer
Favorite
(P 425) EXPLORING MECHANISMS OF EGFR INHIBITOR RESISTANCE IN CHORDOMA
Josh Sommer
Favorite
Song, Danjun

Department of Interventional Radiology，Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China.
(P 164) CLINICAL BENEFITS OF RIPRETINIB AND CYTOREDUCTIVE SURGERY IN IMATINIB-RESISTANT ADVANCED GASTROINTESTINAL STROMAL TUMORS (GISTS): A RETROSPECTIVE DUAL-CENTER STUDY
Danjun Song
Favorite
Song, Hyojin

University of Calgary
(P 327) CHARACTERIZATION OF TWO NOVEL IMMUNE COMPETENT, MURINE MODELS OF SOFT TISSUE SARCOMA
Hyojin Song
Favorite
(P 422) COMPARISON OF ANNOTATION METHODS FOR PAN-SARCOMA SINGLE CELL DATA
Hyojin Song
Favorite
(P 424) CROSS-COHORT INTEGRATION AS A STRATEGY TO CLASSIFY IMMUNE CHECKPOINT BLOCKADE RESPONSE IN SARCOMA
Hyojin Song
Favorite
Song, Sanghoon

Lunit
(P 123) ARTIFICIAL INTELLIGENCE-POWERED MITOSIS EVALUATION TO COMPLEMENT HUMAN MITOTIC RATE INTERPRETATION IN PREDICTING PROGNOSIS IN LIPOSARCOMA
Sanghoon Song
Favorite
Song, Yunjie

Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co.
(P 83) PREDICTION OF HIGH-RISK OSTEOSARCOMA PATIENTS BASED ON MACHINE LEARNING USING TRANSCRIPTOME AND METHYLATION DATA FROM SGH-COHORT
Yunjie Song
Favorite
Song, Zheng-Qing

Zhongshan Hospital, Fudan University, Shanghai, China
(P 416) TRIPLR COMNINATION THERAPY IN THE FIRST-LINE TREATMENT OF SOFT TISSUE SARCOMA WITH HIGH TUMOR BURDEN: INTERIM ANALYSIS FROM ALTER-S007 STUDY
Zheng-Qing Song
Favorite
Soo, Khee Chee

Singapore General Hospital
(P 375) FROM SAPLING TO SHADE: GROWTH OF A HIGH VOLUME ASIAN TERTIARY SARCOMA SPECIALISED CENTRE
Khee Chee Soo
Favorite
Soragni, Alice

University of California, Los Angeles
(P 27) SUMO2 INHIBITION REVERSES ABERRANT EPIGENETIC REWIRING DRIVEN BY SYNOVIAL SARCOMA FUSION ONCOPROTEINS AND IMPAIRS SARCOMAGENESIS
Alice Soragni
Favorite
Soucek, Laura

Institució Catalana de Recerca i Estudis Avançats (ICREA), Vall d'Hebron Institute of Oncology (VHIO), Peptomyc, S.L. Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona
(P 408) OSTEOMYC: A PHASE 2 PILOT STUDY TO EVALIATE THE SAFETY AND THE ANTITUMOR ACTIVITY OF THE MYC INHIBITOR OMO-103 ADMINISTERED INTRAVENOUSLY IN PATIENTS WITH ADVANCED HIGH GRADE OSTEOSARCOMA
Laura Soucek
Favorite
Sousa, Débora

A.C.Camargo Cancer Center
(P 300) GASTROINTESTINAL STROMAL TUMORS (GIST) IN YOUNG ADULTS (YA): A BRAZILIAN COHORT OF PATIENTS
Débora Sousa
Favorite
Soyfer, Viacheslave

Tel Aviv Medical Center, Tel Aviv, Israel
(P 350) MONITORING CHANGES IN FEMORAL BONE STRENGTH IN PATIENTS WITH METASTATIC BONE DISEASE TREATED WITH RADIATION THERAPY
Viacheslave Soyfer
Favorite
Spaanderman, Douwe

Erasmus Medical Center
(P 154) PREOPERATIVE CLASSIFICATION OF NERVE SHEATH TUMORS USING RADIOMICS-BASED MACHINE LEARNING
Douwe Spaanderman
Favorite
Spadazzi, Chiara

Istituto Romagnolo per lo studio dei Tumori "Dino Amadori" IRST IRCCS, Preclinic and Osteoncology Unit, Meldola, Italy
(P 336) IMPROVEMENT OF PHOTODYNAMIC THERAPY IN SARCOMA: IN VITRO VALIDATION ON OSTEOSARCOMA AND MYXOFIBROSARCOMA
Chiara Spadazzi
Favorite
Spalek, Mateusz

Maria Sklodowska-Curie National Research Institute of Oncology
(P 378) INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG
Mateusz Spalek
Favorite
Spentzos, Dimitris

Massachusetts General Hospital
(P 107) DOES THE USE OF ADJUVANT CHEMOTHERAPY IN LOCALIZED, RESECTABLE SOFT TISSUE SARCOMA LEAD TO BETTER SURVIVAL OUTCOMES? - A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Dimitris Spentzos
Favorite
Spierings, Diana

University Medical Centre Groningen
(P 03) CDK4 IS CO-AMPLIFIED WITH EITHER TP53 PROMOTER GENE FUSIONS OR MDM2 THROUGH DISTINCT MECHANISMS IN OSTEOSARCOMA
Diana Spierings
Favorite
Spinella, Michael

University of Illinois Urbana-Champaign
(P 79) NOVEL THERAPEUTIC POTENTIAL THROUGH HYPERACTIVATION OF THE ANTICIPATORY UNFOLDED PROTEIN RESPONSE PATHWAY IN BONE CANCER TREATMENT
Michael Spinella
Favorite
Spitz, Doug

University of Iowa
(P 12) GENETIC LANDSCAPE OF MPNST DETERMINES METABOLIC STRATEGIES AND THERAPEUTIC OPPORTUNITIES FOR COPING WITH REDOX STRESS
Doug Spitz
Favorite
Sprott, Kam

Deciphera Pharmaceuticals, LLC
(P 181) UPDATED OVERALL SURVIVAL WITH RIPRETINIB VS SUNITINIB IN PATIENTS WITH SECOND-LINE ADVANCED GASTROINTESTINAL STROMAL TUMOR AND KIT EXON 11+17/18 MUTATIONS: CIRCULATING TUMOR DNA ANALYSIS FROM INTRIGUE
Kam Sprott
Favorite
Spunt, Sheri

ImmunoGen
(P 205) MULTI-MODAL TREATMENT IS ASSOCIATED WITH IMPROVED SURVIVAL IN AYA PATIENTS WITH METASTATIC NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA
Sheri Spunt
Favorite
(P 356) RADIATION PRACTICE PATTERNS AND OUTCOMES IN ADOLESCENT YOUNG ADULT PATIENTS WITH VISCERAL NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA
Sheri Spunt
Favorite
Spurzem, Graham

University of California, San Diego
(P 167) DEFINING TEXTBOOK OUTCOMES FOR MINIMALLY INVASIVE SURGICAL RESECTION OF SMALL GASTROINTESTINAL STROMAL TUMORS (GIST) OF THE STOMACH
Graham Spurzem
Favorite
Srikanthan, Amirrtha

The Ottawa Hospital
(P 320) WHAT IS THE ROLE OF CHEMOTHERAPY IN PATIENTS (PTS) WITH SPINDLE CELL/SCLEROSING RHABDOMYOSARCOMA (SCRMS): A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Amirrtha Srikanthan
Favorite
Srivastava, Abhilasha

Northwestern University, Feinberg School of Medicine
(P 222) ANALYSIS OF THE CITN-13 SARCOMA ARM: PEMBROLIZUMAB AND INTERFERON GAMMA FOR SYNOVIAL SARCOMA AND MYXOID/ ROUND CELL LIPOSARCOMA
Abhilasha Srivastava
Favorite
Stacchiotti, Silvia

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 37) HEALTH-RELATED QUALITY OF LIFE FROM A PHASE 4 STUDY TO EVALUATE DISCONTINUATION AND RECHALLENGE OF PEXIDARTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR PREVIOUSLY TREATED WITH PEXIDARTINIB
Silvia Stacchiotti
Favorite
(P 43) SAFETY AND EFFICACY WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY
Silvia Stacchiotti
Favorite
(P 44) TUMOR RESPONSE AND REGROWTH IN RELATION TO CLINICAL EVENTS AMONG PEXIDARTINIB-TREATED SUBJECTS IN THE PHASE 3 ENLIVEN TRIAL
Silvia Stacchiotti
Favorite
(P 110) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF PLEOMORPHIC RHABDOMYOSARCOMA (P-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Silvia Stacchiotti
Favorite
(P 111) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA (S-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Silvia Stacchiotti
Favorite
(P 137) TARGETING PRIMARY AND SECONDARY ONCOGENIC DRIVERS IN RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMAS
Silvia Stacchiotti
Favorite
(P 234) IMMUNOSARC II MASTER TRIAL (PHASE II OF SUNITINIB AND NIVOLUMAB): RESULTS FROM THE CLEAR CELL SARCOMA (CCS) COHORT. A GEIS, ISG, AND UCL STUDY
Silvia Stacchiotti
Favorite
(P 415) TRABECTEDIN PLUS OLAPARIB IN ADVANCED LEIOMYOSARCOMA PROGRESSING AFTER STANDARD TREATMENTS FOR ADVANCED DISEASE: A POOLED ANALYSIS OF TOMAS AND TOMAS2 STUDIES FROM THE ITALIAN SARCOMA GROUP.
Silvia Stacchiotti
Favorite
(P 429) PATIENTS WITH ADVANCED EPITHELIOID HEMANGIOENDOTHELIOMA TREATED WITH SIROLIMUS: OUTCOME FOLLOWING SIROLIMUS DISCONTINUATION.
Silvia Stacchiotti
Favorite
Stanhope, Stephen

Boehringer Ingelheim Pharmaceuticals Inc
(P 133) REAL-WORLD ANALYSIS OF DEDIFFERENTIATED LIPOSARCOMA (DDLPS) IN A US COMMUNITY ONCOLOGY SETTING
Stephen Stanhope
Favorite
Stanicic, Filip

ZRx Outcomes Research Inc.
(P 55) CHONDROSARCOMA PATIENT CHARACTERISTICS AND DIAGNOSTIC AND TREATMENT PATHWAYS: GLOBAL CHONDROSARCOMA PATIENT REGISTRY
Filip Stanicic
Favorite
Stanley, Elizabeth

Boehringer Ingelheim Pharmaceuticals, Inc.
(P 133) REAL-WORLD ANALYSIS OF DEDIFFERENTIATED LIPOSARCOMA (DDLPS) IN A US COMMUNITY ONCOLOGY SETTING
Elizabeth Stanley
Favorite
Stark, Germa'n

Biomage Ltd
(P 222) ANALYSIS OF THE CITN-13 SARCOMA ARM: PEMBROLIZUMAB AND INTERFERON GAMMA FOR SYNOVIAL SARCOMA AND MYXOID/ ROUND CELL LIPOSARCOMA
Germa'n Stark
Favorite
Starmans, Martijn

Erasmus Medical Center
(P 154) PREOPERATIVE CLASSIFICATION OF NERVE SHEATH TUMORS USING RADIOMICS-BASED MACHINE LEARNING
Martijn Starmans
Favorite
Statz-Geary, Kurt

University of Miami/ Jackson Memorial Hospital
(P 224) COMPREHENSIVE EVALUATION OF DNA DAMAGE RESPONSE PATHWAY ALTERATIONS AND ASSOCIATED IMMUNOTHERAPY-RESPONSE BIOMARKERS IN SARCOMAS
Kurt Statz-Geary
Favorite
Stebegg-Wagner, Marisa

iOmx AG
(P 337) OMX-0407 A NOVEL SPECTRUM-SELECTIVE SMALL MOLECULE KINASE INHIBITOR IS ACTIVE IN THE TREATMENT OF ANGIOSARCOMA
Marisa Stebegg-Wagner
Favorite
Steeghs, Neeltje

The Netherlands Cancer Institute
(P 24) NEOADJUVANT CHEMOTHERAPY FOR RADIOTHERAPY ASSOCIATED ANGIOSARCOMA (RAAS) OF THE BREAST IMPROVES ONCOLOGICAL OUTCOMES
Neeltje Steeghs
Favorite
(P 349) LONG-TERM SURVIVAL OF PARTICIPANTS IN THE PASART-1 AND PASART-2 TRIALS OF NEO-ADJUVANT PAZOPANIB AND RADIOTHERAPY IN SOFT TISSUE SARCOMA
Neeltje Steeghs
Favorite
Stegmaier, Kimberly

Dana Farber
(P 66) EWING TUMORS WITH STAG2 LOSS DEMOSNTRATE ALTERED INTERFERON SIGNATURES AND IMPAIRED CXCL10 EXPRESSION
Kimberly Stegmaier
Favorite
Steiner, Sabrina

Pathology and Molecular Pathology
(P 99) ACQUIRED NF2 MUTATION CONFERS RESISTANCE TO TRK INHIBITION IN AN EX VIVO LMNA::NTRK1-REARRANGED SOFT TISSUE SARCOMA CELL MODEL
Sabrina Steiner
Favorite
Stella, Valavanis

Moffitt Cancer Center
(P 309) PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT SOFT TISSUE SARCOMA: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Valavanis Stella
Favorite
Stencel, Sean

Northwestern University, Feinberg School of Medicine, Department of Medicine, Division of Oncology
(P 179) PRIMARY MANAGEMENT OF LOCALIZED GASTROINTESTINAL STROMAL TUMORS WITH IMATINIB MONOTHERAPY: AN ALTERNATIVE TO RESECTION FOR PATIENTS PRECLUDED FROM SURGERY
Sean Stencel
Favorite
Sternheim, Amir

National Unit of Orthopaedic Oncology, Tel Aviv Medical Center, Tel Aviv University
(P 350) MONITORING CHANGES IN FEMORAL BONE STRENGTH IN PATIENTS WITH METASTATIC BONE DISEASE TREATED WITH RADIATION THERAPY
Amir Sternheim
Favorite
Steuerwald, Nury

Levine Cancer Institute
(P 430) QUANTITATIVE EMT GENE SCORES AT DIAGNOSIS INDICATE METASTASIS RISK AND SURVIVAL IN SYNOVIAL SARCOMA
Nury Steuerwald
Favorite
Stewart, Clinton

St. Jude Children's Research Hospital
(P 288) ANGIOA: A SAFETY AND TOLERABILITY STUDY OF TRIPLE ANTI-ANGIOGENIC THERAPY COMBINED WITH PD-L1 BLOCKADE IN PEDIATRIC, ADOLESCENT AND YOUNG ADULT RECURRENT/REFRACTORY SOLID TUMORS
Clinton Stewart
Favorite
Stewart, Elizabeth

St. Jude Children's Research Hospital
(P 288) ANGIOA: A SAFETY AND TOLERABILITY STUDY OF TRIPLE ANTI-ANGIOGENIC THERAPY COMBINED WITH PD-L1 BLOCKADE IN PEDIATRIC, ADOLESCENT AND YOUNG ADULT RECURRENT/REFRACTORY SOLID TUMORS
Elizabeth Stewart
Favorite
stracuzzi, alessandra

BAMBINO GESU CHILDREN HOSPITAL
(P 298) EWING SARCOMA OF MAXILLOFACIAL REGION AND SKULL: A RETROSPECTIVE MONOINSTITUTIONAL PEDIATRIC SERIES
alessandra stracuzzi
Favorite
Strauss, Dirk

The Royal Marsden Hospital
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
Dirk Strauss
Favorite
Strauss, Sandra

UCL Cancer Institute, University College London NHS Foundation Trust
(P 23) METASTATIC ALVEOLAR SOFT PART SARCOMA: PREGNANCY-RELATED WORSENING AND SPONTANEOUS EXCEPTIONAL REMISSION POSTPARTUM- A CASE REPORT.
Sandra Strauss
Favorite
Strauss, Sandra

University College, London
(P 60) DIAGNOSIS AND MANAGEMENT OF PAEDIATRIC EWING SARCOMA PATIENTS IN ENGLAND 2014-2017: A COMPARISON OF NATIONAL DATA WITH THE EURO-EWING 2012 CLINICAL TRIAL
Sandra Strauss
Favorite
Strauss, Sandra

UCL Cancer Institute, University College London NHS Foundation Trust
(P 185) ADDRESSING THE GAP FOR SYMPTOM CONTROL THROUGH THE IMPLEMENTATION OF ENHANCED SUPPORTIVE CARE AT THE LONDON SARCOMA SERVICE
Sandra Strauss
Favorite
(P 234) IMMUNOSARC II MASTER TRIAL (PHASE II OF SUNITINIB AND NIVOLUMAB): RESULTS FROM THE CLEAR CELL SARCOMA (CCS) COHORT. A GEIS, ISG, AND UCL STUDY
Sandra Strauss
Favorite
Stricker, Thomas

One Oncology
(P 427) MULTI-OMIC AND MULTI-REGION PROFILING OF DESMOID TUMORS REVEALS INTRA- AND INTER-TUMOR HETEROGENEITY
Thomas Stricker
Favorite
Stucchi, Erika

IRCCS Humanitas Research Hospital
(P 124) ASSESSMENT OF THE MECHANISMS OF ACTION OF ERIBULIN IN PATIENTS WITH ADVANCED LIPOSARCOMA THROUGH THE EVALUATION OF THE RADIOLOGICAL, FUNCTIONAL AND TISSUE RESPONSE: A MONOCENTRIC PROSPECTIVE STUDY
Erika Stucchi
Favorite
(P 290) ARTIFICIAL INTELLIGENCE-BASED COMPARISON OF ADULT AND ADOLESCENT AND YOUNG ADULTS (AYA) SARCOMAS: A PILOT STUDY
Erika Stucchi
Favorite
Studer, Gabriela

SwissSarcomaNetwork
(P 184) A SYSTEMATIC REVIEW ABOUT CLINICAL PROGNOSTIC MODELS FOR SARCOMAS
Gabriela Studer
Favorite
Studer, Gabriela

University Hospital, Luzern; Swiss Sarcoma Network
(P 204) IMPACT OF UNPéLANNED EXCISION ON THE SURVIVAL OF SARCOMA PATIENTS - A TARGET TRIAL EMULATION
Gabriela Studer
Favorite
Stutzman, Sonja

University of Texas Southwestern Medical Center
(P 417) VITAS: ATEZOLIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR PEDIATRIC RELAPSED/REFRACTORY SOLID TUMORS: AN OPEN-LABEL, PHASE I/II, SINGLE-ARM, MULTI-CENTER TRIAL IN PROGRESS
Sonja Stutzman
Favorite
Styring, Emelie

Skåne University Hospital
(P 03) CDK4 IS CO-AMPLIFIED WITH EITHER TP53 PROMOTER GENE FUSIONS OR MDM2 THROUGH DISTINCT MECHANISMS IN OSTEOSARCOMA
Emelie Styring
Favorite
Suarez-Navarro, Julissa

University of California Davis
(P 08) ELUCIDATING THE ROLE OF YAP IN SARCOMA DEVELOPMENT
Julissa Suarez-Navarro
Favorite
Subbiah, Vivek

MD Anderson Cancer Center
(P 47) A PHASE 2 STUDY OF OLAPARIB IN METASTATIC IDH1 AND IDH2 MUTANT CHONDROSARCOMAS
Vivek Subbiah
Favorite
Subhawong, Ty

University of Miami
(P 358) RADIOMIC EVALUATION OF MRIS IN PATIENTS WITH SOFT TISSUE SARCOMA TREATED WITH STEREOTACTIC BOSY RADIATION THERAPY
Ty Subhawong
Favorite
Subramaniam, Aparna

The University of Texas MD Anderson Cancer Center
(P 398) PREDICTORS OF EFFICACY IN PATIENTS WITH SOFT TISSUE SARCOMAS TREATED WITH PAZOPANIB
Aparna Subramaniam
Favorite
Sukovich, Jonathan

University of Michigan
(P 341) THE EFFECTS OF ULTRASOUND-GUIDED HISTOTRIPSY ON SOFT TISSUE SARCOMA
Jonathan Sukovich
Favorite
Sullivan, Mikaela

Mayo Clinic
(P 278) ROTATIONPLASTY AS AN EFFECTIVE LIMB SALVAGE OPTION IN THE ADULT POPULATION
Mikaela Sullivan
Favorite
(P 294) COMPARING HIGH-GRADE NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA IN ADULT AND PEDIATRIC POPULATIONS
Mikaela Sullivan
Favorite
(P 307) OUTCOMES OF PEDIATRIC NON-RHABDOMYOSARCOMA SOFT-TISSUE SARCOMAS OF THE EXTREMITIES
Mikaela Sullivan
Favorite
Summers, Corrine

Seattle Children's Hospital, University of Washington
(P 226) EARLY EXPERIENCE ON ENLIGHTEN-01: A PHASE 1 STUDY OF BISPECIFIC ADAPTER MOLECULE- CONTROLLED FOLATE RECEPTOR CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY OSTEOSARCOMA
Corrine Summers
Favorite
Sundvold, Vibeke

Lytix Biopharma AS
(P 243) MYELOSUPPRESSION FOLLOWING LYMPHODEPLETING CHEMOTHERAPY AS PART OF ADOPTIVE CELL THERAPY FOR PATIENTS WITH PROGRESSIVE SOFT TISSUE SARCOMA AFTER STANDARD CHEMOTHERAPY
Vibeke Sundvold
Favorite
Sun, Lili

Vanderbilt University Medical Center
(P 199) FINANCIAL TOXICITY AMONG SARCOMA PATIENTS AND ASSOCIATED FACTORS
Lili Sun
Favorite
(P 297) ESTABLISHING A PEDIATRIC, ADOLESCENT AND YOUNG ADULT COHORT OF SARCOMA PATIENTS TO STUDY ONCOLOGIC AND NON-ONCOLOGIC OUTCOMES
Lili Sun
Favorite
sun, mengxiong

Shanghai General Hospital, School of Medicine Shanghai Jiao Tong University
(P 48) A SINGLE-ARM, OPEN-LABEL CLINICAL STUDY OF OVV-01 ONCOLYTIC VIRUS INJECTION AS MONOTHERAPY OR IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS FOR ADVANCED SOLID TUMOR PATIENTS
mengxiong sun
Favorite
(P 90) TARGETING HIGH RISK MYC- AMPLIFIED OSTEOSARCOMA BY AURORA KINASE INHIBITOR--RESULT FROM A NGS BASED UMBRELLA TRIAL
mengxiong sun
Favorite
Sun, Wei

Department of Orthopaedics, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai Bone Tumor Institution, Shanghai, China
(P 48) A SINGLE-ARM, OPEN-LABEL CLINICAL STUDY OF OVV-01 ONCOLYTIC VIRUS INJECTION AS MONOTHERAPY OR IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS FOR ADVANCED SOLID TUMOR PATIENTS
Wei Sun
Favorite
(P 83) PREDICTION OF HIGH-RISK OSTEOSARCOMA PATIENTS BASED ON MACHINE LEARNING USING TRANSCRIPTOME AND METHYLATION DATA FROM SGH-COHORT
Wei Sun
Favorite
(P 90) TARGETING HIGH RISK MYC- AMPLIFIED OSTEOSARCOMA BY AURORA KINASE INHIBITOR--RESULT FROM A NGS BASED UMBRELLA TRIAL
Wei Sun
Favorite
sun, wenyue

nih
(P 152) NOVEL PAX3::MAML3 FUSION IDENTIFIED IN ALVEOLAR RHABDOMYOSARCOMA: USING DNA METHYLATION TO EXPANDE THE GENETIC SPECTRUM OF "FUSION POSITIVE" CASES
wenyue sun
Favorite
SUTO, HIROTAKA

Hyogo Cancer Center
(P 168) EFFICACY OF LOW-DOSE IMATINIB IN A PATIENT WITH A GIST WITH KIT EXON 11 W557_K558 DELETION
HIROTAKA SUTO
Favorite
Suzi, Birz

University of Chicago
(P 287) AN INTERNATIONAL SURVEY OF PROVIDER PRACTICES REGARDING BONE MARROW SAMPLING VERSUS [18F] FDG PET/CT IN THE DIAGNOSTIC EVALUATION OF BONE MARROW METASTASIS IN PEDIATRIC RHABDOMYOSARCOMA
Birz Suzi
Favorite
Suzuki, Rie

Osaka International Cancer Institute
(P 05) DEVELOPMENT OF SARCOMA ORGANOID MODELS WITH AIR-LIQUID INTERFACE ORGANOID CULTURES
Rie Suzuki
Favorite
(P 96) TRACP-5B AS A BIOMARKER FOR LONG-TERM DENOSUMAB TREATMENT OF UNRESECTABLE GIANT CELL TUMOR OF BONE
Rie Suzuki
Favorite
(P 272) OUTCOMES OF FOUR CASES OF TOTAL HIP ARTHROPLASTY (THA) WITH POROUS TANTALUM IMPLANT AFTER PARTIAL ACETABULAR RESECTION USING 3D PREOPERATIVE PLANNING FOR PELVIC BONE TUMORS
Rie Suzuki
Favorite
(P 283) USE OF MIXED REALITY IN PELVIC BONE TUMOR RESECTION: FIVE CASE STUDY
Rie Suzuki
Favorite
(P 387) SUCCESSFUL PAZOPANIB TREATMENT OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA WITH COAMPLIFICATION OF PDGFRA, VEGFR2, AND KIT: A CASE REPORT
Rie Suzuki
Favorite
Svane, Inge Marie

National Center for Cancer Immune Therapy, Department of Oncology, Herlev Hospital
(P 243) MYELOSUPPRESSION FOLLOWING LYMPHODEPLETING CHEMOTHERAPY AS PART OF ADOPTIVE CELL THERAPY FOR PATIENTS WITH PROGRESSIVE SOFT TISSUE SARCOMA AFTER STANDARD CHEMOTHERAPY
Inge Marie Svane
Favorite
Sveinbjornsson, Baldur

Lytix Biopharma AS
(P 243) MYELOSUPPRESSION FOLLOWING LYMPHODEPLETING CHEMOTHERAPY AS PART OF ADOPTIVE CELL THERAPY FOR PATIENTS WITH PROGRESSIVE SOFT TISSUE SARCOMA AFTER STANDARD CHEMOTHERAPY
Baldur Sveinbjornsson
Favorite
Swallow, Carol

Princess Margaret Cancer Centre, University Health Network and Mount Sinai Hospital
(P 376) IMPACT OF SITE OF ORIGIN ON THE PROGNOSIS OF PATIENTS WITH PRIMARY RESECTABLE NON-UTERINE ABDOMINAL LEIOMYOSARCOMA
Carol Swallow
Favorite
(P 378) INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG
Carol Swallow
Favorite
Swallow, Carol

The Princess Margaret/Mount Sinai Hospital
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
Carol Swallow
Favorite
Swaney, William

Expression Therapeutics
(P 106) DELTAREX-G, A TUMOR TARGETED CCNG1 INHIBITOR, DEMONSTRATES CLINICAL BENEFIT IN ADVANCED CHEMORESISTANT SARCOMA FOLLOWING FDA CBER AUTHORIZATION FOR USE AS PLATFORM THERAPY WITH FDA APPROVED DRUGS
William Swaney
Favorite
Swayambunathan, Jay

Department of Orthopaedic Surgery, Duke University
(P 148) ISOCITRATE DEHYDROGENASE MUTATIONS IN CHONDROSARCOMA: A META-ANALYSIS
Jay Swayambunathan
Favorite
Sweeney, Kyle

University of Kansas Medical Center
(P 36) EARLY REAL-WORLD EXPERIENCE WITH THE USE OF NIROGACESTAT FOR THE TREATMENT OF DESMOID FIBROMATOSIS
Kyle Sweeney
Favorite
(P 271) OUTCOMES OF DISTAL FEMORAL REPLACEMENT VS INTERNAL FIXATION FOR METASTATIC BONE DISEASE OF THE DISTAL FEMUR
Kyle Sweeney
Favorite
Sweet-Cordero, Alejandro

UCSF
(P 49) A WORKING GROUP FOR THE DEVELOPMENT OF A CLINICAL FRAMEWORK THAT STRATIFIES OSTEOSARCOMA PATIENTS USING BIOMARKERS OF CLINICAL RISK AND BIOLOGY
Alejandro Sweet-Cordero
Favorite
(P 65) EPIGENETIC HETEROGENEITY AND STATE SPECIFIC TRANSCRIPTIONAL PROGRAMS DRIVE DRUG RESPONSE IN OSTEOSARCOMA
Alejandro Sweet-Cordero
Favorite
(P 292) CHARACTERIZATION OF TELOMERE MAINTENANCE MECHANISMS IN OSTEOSARCOMA PATIENT-DERIVED LABORATORY MODELS
Alejandro Sweet-Cordero
Favorite
(P 295) DEFINING OSTEOSARCOMA HETEROGENEITY: CONSENSUS CLUSTERING REVEALS GENE EXPRESSION SUBTYPES
Alejandro Sweet-Cordero
Favorite
Swilling, Aubrey

The University of Kansas Medical Center
(P 36) EARLY REAL-WORLD EXPERIENCE WITH THE USE OF NIROGACESTAT FOR THE TREATMENT OF DESMOID FIBROMATOSIS
Aubrey Swilling
Favorite
Swinkels, Maisie

UCLH
(P 146) EXPLORING THE CLINICAL UTILITY OF WHOLE GENOME SEQUENCING FOR PAEDIATRIC, TYA AND ADULT SARCOMA PATIENTS WITHIN THE LONDON SARCOMA SERVICE: A RETROSPECTIVE COHORT ANALYSIS
Maisie Swinkels
Favorite
Switaj, Tomasz

Maria Sklodowska-Curie National Research Institute of Oncology
(P 245) PRELIMINARY RESULTS FROM A PHASE 2 EFTISARC-NEO TRIAL OF NEOADJUVANT SOUBLE LAG-3 PROTEIN EFTILAGIMOD ALPHA, PEMBROLIZUMAB, AND CONCURRENT RADIOTHERAPY IN PATIENTS WITH RESECTABLE SOFT TISSUE SARCOMA
Tomasz Switaj
Favorite
Szumera-Cieckiewicz, Anna

Maria Sklodowska-Curie National Research Institute of Oncology
(P 77) MULTI-PARAMETRICAL PROFILING OF CHONDROSARCOMA
Anna Szumera-Cieckiewicz
Favorite
(P 245) PRELIMINARY RESULTS FROM A PHASE 2 EFTISARC-NEO TRIAL OF NEOADJUVANT SOUBLE LAG-3 PROTEIN EFTILAGIMOD ALPHA, PEMBROLIZUMAB, AND CONCURRENT RADIOTHERAPY IN PATIENTS WITH RESECTABLE SOFT TISSUE SARCOMA
Anna Szumera-Cieckiewicz
Favorite